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Three Streptococcal strains: S. milleri P213, S. milleri P35 and S. milleri B200 and three
enterococcal strains: E. faecalis 123, E. faecalis 126 and E. faecium were used to test for
vancomycin resistance. Two strains were used as reference strains that were already
characterized as vancomycin resistant. E. faecium BM4147 was used as a VanA control
and E. faecalis ATCC was used as a VanB control. Susceptibility of each strain to this
antibiotic was tested by disk-diffusion assay and the MIC values for the strains were found
to be between 5 - 10 Ilg/ml and for the VanA control, the MIC was> 64 Ilg/ml and for the
VanB control was 32 Ilg/ml. These MIC values indicate that S. milleri P213, S. milleri
P35, S. milleri B200, E. faecalis 123, E. faecalis 126, and E. faecium are all of the VanC
phenotype. All strains were tested for lysis by means of addition of vancomycin (10
Ilg/ml) to the bacterial cultures. Lytic curves were constructed and the VanB control was
found to be most autolytic upon addition of vancomycin and E. faecalis 123 was the least
autolytic. However, under normal conditions in phosphate buffer, lytic curves showed that
S. milleri P213 was the most autolytic and the VanA control, the least autolytic. PCR
assays were performed to detect specific antibiotic resistant genes. Primers were selected
from Dukta-Malen et al., 1995. The VanA primer yielded amplification of732 bp for only
the VanA control DNA and the VanB primer set yielded products for the VanB control
DNA. S. milleri P213, P35, B200 and E. faecalis 123 and 126, and E. faecium DNA were
amplified with the VanC primers. This supports the results obtained in MIC that these
strains are possibly VanC resistant strains. Amplified VanA control and that of E. faecalis
126 were thereafter sequenced. VanA control amplicon was correctly amplified since it
showed homology to E. faecium BM4147 as well as the VanB amplicons which was found
to be homologous to the transposon Tn1549 found on the well-characterized E. faecalis
strain which is known to harbour the VanB vancomycin-resistant genes. Whilst E. faecalis
126 which represented the VanC phenotype showed 96% homology to E. gallinarum
BM4147 which is a well-characterized glycopeptide-resistant enterococci belonging to the
VanC phenotype. Southern blots were performed using specific primers as a probe to
verify whether the gene sequences for the specific genotype were present in these strains
and results confirmed those found in the PCR assays and in DNA sequencing. The
peptidoglycan precursors of each strain were arrested in vancomycin (20 Ilg/ml) to block
transpeptidation and transglycosylation steps of peptidoglycan synthesis and bacitracin
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(1 00 ~g/ml) was used to amplify precursors at the transglycosylation step. Precursors were
extracted and analysed by reverse-phase HPLC. UDP-MurNAc-tetrapeptides cell wall
precursors, which are found abundantly in vancomycin-resistant strains, were found in
large proportions in all strains, except in E. faecalis 123 when arrested with vancomycin.
This precursor has a noticeably decreased affinity for vancomycin, hence contributing to
its resistance. The precursor accumulated when arrested with bacitracin, was, UDP-
MurNAc-tetrapeptide in all strains except in E. faecalis 126. UDP-MurNAc-
pentapeptides were also found in moderate amounts in most strains. The molecular masses
of the peptidoglycan precursors obtained from mass spectrometry correctly identified
them. This confirmed that the bacterial strains investigated were in fact resistant to the
antibiotic vancomycin and this study shows that results obtained from conventional
phenotypical screening methods reliably correlated with the genotypes classified using


















CHAPTER ONE - LITERATURE REVIEW 1
1.1. Introduction 2
1.2. Peptidoglycan Biosynthesis 5
1.3. Glycopeptide Resistance Mechanisms 8
















1.8. Aim of the Study 33
VI
CHAPTER TWO- MATERIALS AND METHODS 35
2.1. Bacterial Strains and Growth Conditions 35
2.2. Micro - Titre Plate Dilution Assay 35
2.3. Disk - Diffusion Assay 36
2.4. Lytic Curves 36
2.5. Genomic Isolation 36
2.5.1. Quantitation of DNA 37
2.5.2. Detection and Analysis of Extracted DNA By Agarose Gel
Electrophoresis 37
2.6. Polymerase Chain Reaction 38
2.6.1. PCR Primers 38
2.6.2. DNA Amplification By PCR 39
2.7. Southern BlotlHybridisation 41
2.7.1. Transfer of DNA 41
2.7.2. Oligonucleotide Tailing With DIG-dUTP DAtp 41
2.7.3. Pre - Hybridisation and Hybridisation 41
2.7.4. DIG Nucleic Acid Detection 42
2.8. Analysis of Peptidoglycan Precursors 42
2.9. Mass Spectrometry 43
2.10. DNA Sequencing 43
2.10.1. Big Dye Terminator v3.0 Ready Reaction Cycle Sequencing 43
2.10.2. Purification of Extension Products 44
2.10.3. Sequencing of Extension Products 44
CHAPTER THREE - RESULTS AND DISCUSSION 45
3.1. Micro - Titre Plate Dilution Assay 46
3.2. Disk - Diffusion Assay 48
3.3. Lytic Curves 50
3.4. Genomic Isolation 56
3.5. PCR 57
3.5.1. Using Primers From Miele et al., 1995 58
3.6. Sequencing of PCR Products Generated By Amplification With Miele et al., 62
1995 Primers
vu
3.7. Southern Blot Hybridisation Using Miele et al., 1995 Primers as Probes 69
3.8. PCR Using Primers From Dukta - Malen et al., 1995 72
3.9. Sequencing of PCR Products Generated By Amplification With Dukta - Malen
et al., 1995 Primers 75
3.10. Southern Blotting Using Dukta - Malen et al., 1995 Primers as Probes 82
3.11. Analysis of Peptidoglycan Precursors 85
3.11.1. HPLC Profiles of Precursors Arrested With 20 flg/ml Vancomycin 86
3.11.2. HPLC Profiles of Precursors Arrested With 100 flg/ml Bacitracin 98
3.12. Analysis of Mass Spectrometry Data 108
CHAPER FOUR - CONCLUSION AND FUTURE PROSPECTS





Figure 1.1. Model of the antibiotic, vancomycin (top) connected to a portion of bacterial
cell wall precursor (bottom) by hydrogen bonds indicated by the dashed
lines. The heptapeptide backbone of the antibiotic can be seen running
through the centre of the molecule. The hydrogen bond formed between the
NH and CO groups of the binding pocket along the peptide backbone of the
D-Ala-D-Ala motif of the expanding cell wall, Me, methyl (2, 32).
Page 3
Figure 1.2. Schematic representation of peptidoglycan biosynthesis in glycopeptide-
susceptible (A) and -resistant cells (B) (2).
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Figure 1.3. Mode of action of inhibitors of peptidoglycan synthesis (8).
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Figure 1.4. The bactericidal effect of vancomycin. Vancomycin binds noncovalently via
five hydrogen bonds to the D-Ala-D-Ala terminus of the peptidoglycan
pentapeptide linker. This tight binding of vancomycin inhibits the cross-linking
of the peptidoglycan, lowering the strength of the bacterial cell wall.
Transglycosylation is also inhibited, thus stopping peptidoglycan growth by
blocking the addition ofN- acetylmuramic acid and N-acetylglucosamine (79).
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Figure 1.5. Resistance mechanism of vancomycin by vanHAX type resistance. Conversion
of the terminal D-Ala-D-Ala to D-Ala-D-Lactate occurs through the action
of VanH, VanA, and VanX. Conversion to D-Lac results in vancomycin
binding lower by a 1000-fold.
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Figure 1.6. Sequence of events that lead to transcriptional activation of the vanA and vanB
clusters (6).
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Figure 1.7. Schematic representation of the vanA gene cluster illustrating regulation of the
PR and the PH promoters (6).
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Figure 1.8. Schematic map of transposable element, Tn1546. Coding sequences are
denoted by open arrows whilst those closed and open arrows labelled IRL and
IRR specify the left and right inverted repeats of the transposon, respectively.
The promoter found in the vanS-vanH intergenic region co-transcribes vanH,
vanA, and vanX(2, 35,43).
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Figure 1.9. Schematic map of the vanB gene cluster (24).
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buffer served as a control of autolysis. Page 52
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Figure 3.5. Vancomycin induced autolysis assay of E. faecium. Strain in phosphate
buffer served as a control of autolysis.
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buffer served as a control of autolysis.
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Figure 3.11. 0.8% (w/v) Agarose gel showing DNA isolated. Lane I: S. milleri 213; Lane
2: S. milleri P35; Lane 3: S. milleri B200; Lane 4: E. faecalis 123; Lane 5: E.




Figure 3.12. Image of PCR Products amplified with Primer VanA. Lane M: Molecular
Weight Marker Ill; Lane 1: S. milleri P213; Lane2: S. milleri B200;
Lane3: S. milleri P35; Lane 4: E. faecalis 123; Lane 5: E. faecalis 126;
Lane 6: Negative Control (No Taq); Lane 7: Negative Control (No DNA).
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In 1958 the glycopeptide antibiotic vancomycin was introduced for the treatment of Gram-
positive bacteria because of the increasing prevalence of methicillin-resistance in
coagulase negative Staphylococcus aureus (MRSA) (17,85,96, 100, 105). Vancomycin
and its structurally related antibiotic, teicoplanin was also thought to be the last resort in
the defence against severe infections caused by other gram-positive organisms such as
Enterococci, Streptococci and Clostridium difficle (5, 10, 13, 30, 33, 45, 46, 48-50, 69, 70,
79, 80, 85, 95, 106). However, Gram negative organisms are intrinsically resistant since
they have impermeable outer membranes (54).
In general, glycopeptides consist of a heptapeptide backbone that is substituted with five to
seven aromatic rings and different sugars. Vancomycin is a large molecule comprising of
two hexoses and five aromatic rings (Figure 1.1.) (46, 72). Vancomycin binds to the
substrates of transglycosylases and transpeptidases involved in the cell wall biosynthesis,
the D-Alanyl-D-Alanine (D-Ala-D-Ala) terminus of the lipid-PP-disaccharide-
pentapeptide. This is in contrast to penicillin, which directly binds to and inhibits these
enzymes. By binding to these enzymes, vancomycin is thought to sterically prevent the
consequent action of both activities of transglycosylases and transpeptidases. This is
achieved by adding disaccharyl pentapeptide units to the growing strand and then cross-
linking peptides within and between peptidoglycan strands on the external face of the
cytoplasmic membrane. The bacterial cell then becomes susceptible to osmotic lysis since
the rigidity of the cell wall is lowered because of the failure to form cross-links between
peptidoglycan intermediates. Hence vancomycin has become the leading therapy for
treating infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and
enterococci (54, 62, 71, 72, 95, 99).
In 1979 the first case of vancomycin resistance in a clinical setting was reported and in
1986 the first plasmid-mediated resistance to glycopeptide antibiotics such as vancomycin
was discovered (45, 46,59,61, 70, 85, 88, 96, 100, 102, 106). Vancomycin was until very
recently one of the most powerful antibiotics that no bacterial cell had resistance to. The
swift emergence of vancomycin resistant strains as life threatening organisms in hospital
settings worldwide, has led to a surge of exhaustive investigations of the molecular









Figure 1.1. Model of the antibiotic, vancomycin (top) connected to a portion of bacterial
cell wall precursor (bottom) by hydrogen bonds indicated by the dashed lines. The
heptapeptide backbone of the antibiotic can be seen running through the centre of the
molecule. The hydrogen bond formed between the NH and CO groups of the binding
pocket along the peptide backbone of the D-Ala-D-Ala motif of the expanding cell wall,
Me, methyl (5, 64).
Medical practitioners and their patients are becoming increasingly concerned of the rapid
emergence and spread of vancomycin resistance, since strains are now intrinsically resistant
to glycopeptides even though some of these strains were previously considered uniformly
susceptible to glycopeptides (22, 57, 65). Those patients who are immunocompromised,
severely debilitated and undergo antimicrobial therapy, usually suffer with infections caused
by vancomycin-resistant Enterococci (VRE) (58, 61). There has been an increase in the
number of reported incidence of infection and colonization of VRE hence there is added
pressure placed on researchers to find antimicrobial drugs to treat these infections. The ease
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with which bacteria acquire resistant genes is a major factor behind the dramatic increase in
resistant strains (93).
Since most VRE already have resistance to multiple drugs and have acquired additional
resistant determinants through mutation and transfer of resistant genes from other species.
This emergence of glycopeptide resistance in Enterococci poses a serious threat since the
efficacy of antibiotic therapy is compromised because there are few alternatives in cases of
resistance or allergy to p-Iactams (10, 41). The widespread of glycopeptide resistance may
also be due to an epidemic of genes that are mobile to varying degrees and an epidemic of
clone carrying those resistant genes (28, 50). Another serious public health concern is the
possibility that vancomycin-resistant genes may be transferred to other gram-positive
organisms since vancomycin-resistant Enterococci may serve as a reservoir for vancomycin
resistant genes. In the future these genes may make their way to more virulent organisms
such as those of the genus Staphylococcus (18, 64).
The high incidence of MRSA and vancomycin use, which are thought to be risk factors for
vancomycin-resistant S. aureus, make the extensive distribution of these organisms an
alarmingly realistic possibility even though there have been only a few reports of S.
aureus isolates with reduced susceptibility to vancomycin (28, 96). In all cases of
glycopeptide resistance reported, resistance seems to be inducible (52). There is a new
urgency to search for novel antibiotics and through these investigations one of the most
sophisticated molecular systems of acquired resistance and a paradigm of genetic
adaptation has been discovered (24, 25, 29, 63). Bacteria that produce antibiotics have
evolved strategies and mechanisms that provide immunity to the action of the antibiotic,
and there is a general consensus that immunity mechanisms may have evolved with
antibiotic biosynthetic genes to protect the producing organisms. In nature evolution of
bacteria towards resistance to antibiotics and even multiple drug resistance exists hence it
is unavoidable. The basic criteria of bacterial resistance are: (i) genetic and involves
genetic differences from the parental strain; (ii) biochemically based on the presence or
absence of a resistance mechanism; (iii) microbiological which results from an increased
minimum inhibitory concentration (MIC) for an antimicrobial agent; (iv) clinically based
on the outcome of therapy; (v) intrinsic whereby the type of resistance is present in all
members of a given species or genus; and (vi) acquired where only certain isolates of a
species or genus have a type of resistance present. There are two phenomena that can be
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associated with the emergence and efficient spread of resistance, i.e., mutations in the
house-keeping structural or regulatory genes or an alternative is through horizontal
acquisition of foreign genetic information (31, 57, 58, 66, 93, 100). The only hope we
have is to delay the emergence and ensuing widespread of resistant bacteria or resistant
genes (31).
Three glycopeptide resistance phenotypes can be distinguished on the basis of the level and
inducibility of resistance to vancomycin and teicoplanin (37). There are two classes of
acquired resistance to glycopeptide antibiotics in Enterococcus, VanA and VanE whilst
Vane is thought to be intrinsic (22,50,84). The most extensively studied phenotype is the
VanA resistant phenotype which led to the elucidation of a mechanism of resistance to
glycopeptides and an insight into the regulation and mode of dissemination of the
corresponding genes (9, 45, 70). Phenotypes VanA and VanE are of the highest clinical
importance since they are the most frequently observed (47, 58, 88, 102, 103). In
Enterococci, acquired resistance is due to the production of peptidoglycan precursors
ending in the depsipeptide D-Alanyl-D-Lactate (D-Ala-D-Lac) instead of the dipeptide D-
Alanine-D-Alanine (D-Ala-D-Ala) found in susceptible bacteria (14, 18,32,52, 72, 103).
1.2. Peptidoglycan Biosynthesis
Peptidoglycan or murein is the major component of the cell wall of the bacteria and is
essential for an organisms survival. It is a macromolecule that surrounds the cell,
determining the shape of the cell as well as maintaining cell integrity (46, 69, 78, 90, 101,
104). Bacterial peptidoglycan may vary between species although some functional elements
are conserved. The glycan strands of all bacterial peptidoglycan are made up of repeat
disaccharide units known as N-acetylglucosamine-N-acetylmuramic acid (GlcNAc-
MurNAc). Glycan chains are cross-linked by short cell wall peptides. The amino group of
the first amino acid in the peptide moiety is linked to the carboxyl group of the lactic acid of
N-acetylmuramic acid by an amide bond. This process occurs in the cytoplasm, membrane
and extracellular cell wall compartments. After synthesis in the cytoplasm, nucleotide
precursors form a phosphodiester bond with an undecaprenol carrier (lipid I) and then lipid II
is formed when lipid I is attached to N-acetylglucosamine. Lastly, penicillin-binding
proteins catalyse the polymerisation of lipid II subunits by the transglycosylation and
5
transpeptidation reactions. Many of the chains run parallel to one another, and are connected
with each other via a peptide moiety of the five amino acids: L-Alanine-D-Glutamic acid-L-
Lysine-D-Ala-D-Ala. The peptide cross-bridges connect the MurNAc residues on the glycan
chains. Cross-links, which makes up the most important component of the cell wall are then
generated (20, 101, 104). Peptidoglycan is closely involved in cell division hence
peptidoglycan biosynthesis is a target for antibiotics although inhibition of its production is
bactericidal (Figure 1.2.) (90). Resistance occurs when the antibiotic does not bind or reach
to its bacterial target and thereby leading to multiple replication of the bacteria (56).
Glycopeptides and moenomycins are known to interfere with the transglycosylation
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Figure 1.2. Schematic representation of peptidoglycan biosynthesis in glycopeptide-
susceptible (A) and -resistant cells (B) (5).
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1.3. Glycopeptide Resistance Mechanisms
For vancomycin to be effective it must reach the cytoplasm and bind with cell wall
precursors thereby inhibiting their incorporation into the growing cell wall (54, 96). Hence
vancomycin is thought to be an effective antibacterial agent as it inhibits peptidoglycan
synthesis (Figure 1.3.) (13, 57, 84). There are two factors which are shown to be critical for
antibacterial activity. These are: dimerization of the vancomycin-group of antibiotics which
results in an enhanced affinity of the antibiotic for cell wall analogs in free solution, and
allows for a chelate effect enhancement of affinity for the bacterial cell wall peptidoglycan.
This is critical since antibiotics, which dimerize weakly are less active than strongly
dimerizing antibiotics. However, if they have initially a greater affinity for bacterial cell wall
analogs then they might be more active. Dimerization of vancomycin-group antibiotics is an
important factor affecting antibiotic activity (17). However there is an escalating problem
since bacteria are now becoming resistant since they produce different cell wall
intermediates (54).
Resistance to vancomycin found in clinical isolates was shown to be inducible and in most
cases transferable, and at times, plasmid mediated (2). Resistance to glycopeptides such as
vancomycin is thought to be phenotypically and genetically heterogenous (30). Vancomycin
alone is bacteriostatic against organisms such as Enterococci (35). Bacteriostasis or bacterial
cell death occurs as a result of disruption of the transglycosylases and or transpeptidases
activity of enzymes responsible for polymerisation and cross-linkage of the cell wall (17).
An alternate biosynthetic pathway for the production of cell wall precursors that bind
vancomycin poorly was found to be the mechanism of acquired glycopeptide resistance in
the VanA and VanB Enterococci (12, 30, 45, 63, 103). Resistance is acquired from the
transfer of mobile genetic elements that encode the enzymes responsible for the synthesis of
low-affinity precursors and the removal of the high-affinity precursors that are normally
produced by the host (13). This is achieved by forming specific hydrogen bonds and other
non-covalent interactions (17). A strategy of reprogramming the terminal peptidoglycan
intermediates in cell-wall cross-linking steps is employed by vancomycin resistance (96).
Glycopeptides inhibit cell wall synthesis due to formation of complexes between the
antibiotic and the C-terminal D-Alanine (D-Ala) residue of peptidoglycan precursors (3-5,
12, 13,30,33,36,48, 53,69, 72, 74, 81, 92, 95, 96, 106). Hence, vancomycin prevents two
steps in peptidoglycan synthesis: transglycosylation and transpeptidation (Figure 1.4.) (46,
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72, 81). Contact with the target can only take place after translocation of the precursors
bound to the lipid carrier to the outer surface of the cytoplasmic membrane since these





















Figure 1.3. Mode ofaction of inhibitors ofpeptidoglycan synthesis (14).
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The transfer of precursors from the lipid carrier to the peptidoglycan is prevented by
transglycosylases by formation of complexes at the outer surface of the cytoplasmic
membrane. Transglycosylases then block the incorporation of the disaccharide pentapeptide
subunits into the growing peptidoglycan (13). Other reactions that are catalysed by
transpeptidases and D, D- carboxypeptidases are also inhibited. It has been revealed by
analysis of cell wall components that various bacterial species show conservation of the C-
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Figure 1.4. The bactericidal effect of vancomycin. Vancomycin binds noncovalently via
five hydrogen bonds to the D-Alanine-D-Alanine terminus of the peptidoglycan pentapeptide
linker. This tight binding of vancomycin inhibits the cross-linking of the peptidoglycan,
lowering the strength of the bacterial cell wall. Transglycosylation is also inhibited, thus
stopping peptidoglycan growth by blocking the addition of N- acetylmuramic acid and N-
acetylglucosamine (85).
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Under normal conditions of peptidoglycan synthesis a ligase enzyme joins two molecules of
D-Alanine to form a D-Ala-D-Ala complex. This complex is then added to the UDP-N-
acetylmuramyl-tripeptide to form the UDP-N-acetylmuramyl-pentapeptide. Glycopeptides
cause the increase of the UDP-N-acetylmuramyl pentapeptide. During transglycosylation the
UDP-N-acetylmuramyl-pentapeptide is incorporated into the nascent peptidoglycan and
permits the formation of cross-bridges during transpeptidation contributing to the strength of
the peptidoglycan layer.
Vancomycin then binds to the D-Ala-D-Ala termini of the pentapeptide precursor units in the
outer surface of the bacterial membrane with high affinity thereby blocking their addition to
the growing peptidoglycan chain. Thus preventing successive cross-linking by blocking the
transglycosylation and transpeptidation reactions resulting in a weaker cell wall (27, 30, 52).
Hence, the D-Ala-D-Ala terminus of peptidoglycan which is a rigid polymer that protects
bacterial cells from osmotic lysis is the molecular target of glycopeptide antibiotics (12, 65,
99). Vancomycin therefore inhibits production of the bacterial cell wall since it acts by
binding irreversibly to terminal D-Ala-D-Ala of the cell wall disaccharide pentapeptide
precursors which eventually results in cell death (27, 46, 65).
Organisms that are glycopeptide resistant avoid cell death by modifying the drug's peptide
target. This is done by specifically modifying it to the depsipeptide D-Ala-D-Lac (16, 34,
65). The substitution of D-Ala-D-Ala for D-Ala-D-Lac in VanA, VanB and VanD
phenotypes of Enterococci prevents binding of glycopeptides to cell wall components and
allows peptidoglycan polymerisation in the presence of the antibiotics (27, 33, 35, 88, 98).
Hence there is a greater than 1000-fold decrease in vancomycin binding when a substitution
of the NH group of the amide D-Ala-D-Ala linkage occurs by an oxygen in a D-Ala-D-Lac
ester linkage (Figure 1.5.) (6, 9, 15,33,37, 53, 57, 80, 85, 86, 95, 99). This replacement of
D-Ala-D-Ala for D-Ala-D-Lac removes a hydrogen bond, which is imperative for antibiotic
binding, thus reducing the glycopeptide's affinity considerably (36, 99, 106). However, the
substitution of D-Ala by D-Ser does not alter the H-bond, but is responsible for
conformational changes which reduce the affinity for vancomycin slightly (30). Because it
binds to the D-Ala-D-Lac terminus with a lower affinity, it is unable to sterically block the
transpeptidation and transglycosylation steps needed for the formation of the peptidoglycan
cell wall(54). The transposable element, Tn1546 present in VRE has the biosynthetic











Figure 1.5. Resistance mechanism of vancomycin by vanHAX type resistance. Conversion
of the terminal D-Alanyl-D-Alanine to D-Alanyl-D-Lactate occurs through the action of
VanH, VanA, and vanX. Conversion to D-Lactate results in vancomycin binding lower by a
1000-fold (85).
In resistant strains, the following genes are expressed, viz., vanA, vanH, van.¥, vanR, and
vanS. The gene products VanR and VanS are members of a two-component regulatory
system required for the vancomycin-induced resistance response by directing transcription of
vanH, vanA and vanK. These genes are responsible for encoding the three proteins
necessary for the synthesis of abnormal peptidoglycan precursors terminating in D-Ala-D-
Lactate (D-Lac) for incorporation into peptidoglycan precursors (5, 6, 9, 15, 16, 24, 25, 33,
45, 46, 53, 65, 84, 85, 103). Several proteins that sense the drug or effect of the drug,
produce a drug-resistant target. Thus eliminating the drug susceptible target in a coordinated
manner responsible for this alteration of the target site for glycopeptide antibiotics (63, 103).
The collective action of the three enzymes VanH, VanA and vanX ensures this alternate
pathway. The origin of these resistant cassettes may have come about from the intrinsic
vancomycin resistant lactic acid bacteria or glycopeptide-producing organisms. An
alternative is that the genes may have arisen through mutations in homologous genes within
Enterococci or that they might have evolved from a common ancestor (64).
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The VanA protein is a ligase of altered substrate specificity which synthesizes D-Ala-D-Lac
in preference of D-Ala-D-Ala whilst the VanH (or VanHs, VanHo) protein is known as a D-
hydroxyacid dehydrogenase which creates a pool of D-Lactate by reducing pyruvate. The
vanX (VanXs) protein is a D, D-dipeptidase lacking activity against D-Ala-D-Lac. This
enzyme minimizes the competing synthesis of normal pentapeptide since it reduces the pools
of D-Ala-D-Ala produced by the native ligase hence inhibits production of glycopeptide-
susceptible precursors (84).
D-hydroxy acids such as D-Lac are neither natural products present in the environment of
some organisms or are not normally produced by organisms such as Enterococci therefore
VanA alone cannot confer resistance to vancomycin. Hence these organisms must acquire
the genes within the vanA operon required to synthesize D-Lac in order to produce the
substrate for VanA (27). The VanA mediated incorporation of D-2-hydroxybutyrate at the
C-terminal position of peptidoglycan precursors allows cell wall synthesis in the presence of
vancomycin (9).
Through investigations, it has been established that vancomycin resistance is due to the
production of peptidoglycan precursors that bind the antibiotic with reduced affinity. Due to
the lfroad substrate specificity ofVanA, VanH and the D-Ala: D-Ala ligase adding enzyme,
the actual binding of the D-Ala substitute incorporated in vivo could not be identified. The
most likely pathway was considered to be the synthesis of a depsipeptide precursor since it
does not catalyse ester bond formation compared to the D-Ala : D-Ala ligase from
susceptible Enterococci (9). Arthur et al. found in their studies that D-Lactate is the most
likely substituent for D-Ala present at the C-terminal position of peptidoglycan precursors
that show low affinity to vancomycin.
VanY and vanZ acts as accessory proteins (13, 70). Even though these two proteins are not
essential for resistance, their production increases the level of resistance to vancomycin and
teicoplanin (13). VanY removes the terminal D-Ala residue from peptidoglycan precursors
and removes vancomycin binding sites by its carboxypeptidase activity (63, 84).
Vancomycin induces the synthesis of two proteins that are readily detectable in Enterococcal
membrane fractions. This is a 39 kDa protein, which was identified as the VanA ligase that
is necessary for cell wall synthesis in the presence of glycopeptides. The other protein is a
D,D-carboxypeptidase of 39.5 kDa, which is required for resistance (5). These two proteins
were only produced after exposure to vancomycin (106). Another model proposes that the
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ligase plays a role in the formation of new pentapeptide precursors which would not bind
vancomycin (52). It has been hypothesized that an inducible carboxypeptidase is involved in
glycopeptide resistance. Gutmann et al. found that induced carboxypeptidase activity of the
high-level resistant strains were greater than that of the two-level resistant strains. In clinical
isolates, Gutmann et al. observed that there is a correlation between the level of resistance
and the carboxypeptidase activity and therefore suggested that the carboxypeptidase is a
functional component of the resistant mechanism.
It has also been suggested that the role of carboxypeptidase could be to decrease the normal
UDP-MurNAc-pentapeptide pool either by cleaving the terminal alanine of this molecule or
by hydrolysing the D-Ala-D-Ala normally added to the UDP-MurNAc-tripeptide (19).
Therefore the low ligase and the high carboxypeptidase activities contribute to vancomycin
resistance since it results in the scarcity of the D-Ala-D-Ala containing precursors (10). AI-
Obeid et aI, has shown that crude walls from non-induced cells or from induced cells treated
with sodium dodecyl sulfate (SDS) to remove the inducible proteins were shown to bind
vancomycin, however cell walls containing cytoplasmic membrane-associated proteins did
not bind vancomycin. Cytoplasmic membranes from vancomycin-induced cells were found
to protect the glycopeptides from being bound to synthetic pentapeptides, however did not
bind vancomycin or teicoplanin. Any subsequent enzymatic modifications of the
pentapeptide precursor of peptides which is considered to be natural targets of glycopeptides
is facilitated by inducible proteins that are responsible for glycopeptide resistance (2).
In a previous study, it has been proposed that cytoplasmic membrane proteins restrict access
of vancomycin to its target. Cell wall-associated membranes which were induced by
vancomycin at low concentrations did not bind vancomycin however it was shown that cell
walls from non-induced cells after being boiled in 4% SDS (w/v) were able to bind
vancomycin. It was used to distinguish between protection of the target site and protection
against non-specific binding to the cell wall. It was also shown experimentally that only
membranes from induced cells prevented binding of vancomycin to exogenous
pentapeptides. From results in some studies it was observed that a component of the
cytoplasmic membrane from vancomycin-induced cells was able to reduce the access of
glycopeptides to the pentapeptide in the natural cell walls of these organisms. It was also
inferred that these proteins are involved in the absence of binding to the glycopeptide target
sites (2).
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The most plausible mechanism of glycopeptide resistance is the binding of the induced
proteins to the pentapeptide and its subsequent modification in such a way that glycopeptide
binding is prevented. Increased susceptibility to penicillin has also been shown to be
accompanied with glycopeptide resistance after the synthesis of these proteins. It is likely
that the proteins after binding and modifying the endogenous pentapeptide, do not allow
normal synthesis of the peptidoglycan by the cell wall enzymes. This might also be inferred
from the altered cell shape of vancomycin-induced strains (2).
The combined substrate specificities of the D-Ala : D-Ala ligases (Ddl), the D-Ala-D-Ala
adding enzymes and the D-Ala-D-Ala termini that interact directly with penicillin-binding
proteins (PBPs) contribute to the incorporation of D-Ala residues into peptidoglycan
precursors (5, 27). Penicillin-binding proteins is involved in the process of cross-linking the
precursors to the growing peptidoglycan, however the replacement of the D-Ala by D-Lac
does not impair cross-linking of the modified precursors to the growing peptidoglycan chain
(27). Analysis of the cell wall peptidoglycans of resistant strains reveal the presence of
altered cross-links compared to that of susceptible strains. Therefore, PBP2A, which is
involved in the biosynthesis of the cell wall, is essential in vancomycin resistance cells
especially in S. aureus strains. This penicillin-binding protein is unable to use D-Ala-D-Lac
as a substrate (94).
The relative pool SIzes of the new UDP-MurNac-tetrapeptide-D-Lac precursor and the
normal residual UDP-MurNAc-pentapeptide determines the level of resistance to
vancomycin. When vancomycin resistance was induced in the presence of vancomycin, the
major impact was a significant decrease in oligomers. After the induction of vancomycin
resistance, an outstanding amount of the normal UDP-MurNAc-pentapeptide precursors
were present during the production of the new UDP-MuNAc-tetrapeptide D-Lac precursor
(54). Billot-Klein et at. found that it is possible that the presence of this pentapeptide
precursor would allow some specific binding of vancomycin, thus impairing the synthesis of
oligomers. Another hypothesis would be that the non-specific binding of vancomycin could
interfere with the synthesis of oligomers (19, 52).
Since resistance in VanA is inducible, it might be that the expression is regulated at the
genetic level. In the VanA Enterococci, the VanR and the VanS proteins are histidine kinase
sensors and forms part of a two-component regulatory system that sense and respond to
environmental stimuli (103, 106). This system regulates the expression of resistant vanA and
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vanE clusters (Figure 1.6.). The VanS protein is autophosphorylated, which in turn
phosphorylates VanR when it detects the presence of vancomycin or teicoplanin or, if it
detects disturbance of cell wall precursors which are elicited by these drugs. When the
system is induced by the presence of vancomycin or teicoplanin not only is there increasing
expression of vanR or vanS, but also the autophosphorylated protein binds to the promoter
region of vanA, vanH, and vanX. This drives transcription of the genes that encode the
essential structural molecules of the gene cluster (19,54,55).
In a laboratory - derived strain, the inactivation of the vanS gene had no effect on the level of
resistance. However, it was shown that the actual level of transcription of resistance genes
decreased. In comparison, the insertional inactivation of the vanR gene was shown to cause
susceptibility to glycopeptides in a vancomycin-resistant lab derived strain and a clinical
isolate. This confirms that vanR is a transcriptional activator and is stimulated by vanS
(106).
For the Vane and VanE phenotype in Enterococci, glycopeptide resistance results from
synthesis of modified precursors ending in D-Alanine-D-Serine (D-Ala-D-Ser).
Glycopeptides exhibit low binding affinities to these modified precursors (13, 35, 84).
Therefore, it can be said that it is the substrate specificity of the enzymes that determine the
structure of the peptidoglycan is responsible for the activity of glycopeptides, and not the





Figure 1.6. Sequence of events that lead to transcriptional activation of the vanA and vanB
clusters (12).
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Another hypothesis is that multiple genes or multiple metabolic pathways are altered because
of long clinical vancomycin exposure times that are required to generate resistance. Some
abnormalities associated with strains such as vancomycin-intermediate S. aureus (VISA) are:
(i) reduced rate of growth, decreased cell wall cross-linking, (ii) increased cell wall
thickness, (iii) decreased autolysis, (iv) changes in PBP's and alterations in glutamate
amidation of the peptidoglycan stem peptide. Thickened, poorly cross-linked cell walls are
thought to be peripheral targets for vancomycin hence trapping the antibiotic before it can
reach its site oflethal action at the cell membrane (58).
1.4. Glycopeptide Resistant Genes
Therapeutic failure may occur as a result of resistant phenotypes that have emerged in
response to glycopeptide therapy in vivo (15). It has been established that resistance to
certain levels of vancomycin and teicoplanin was plasmid-mediated and inducible by sub
inhibitory concentrations of glycopeptide antibiotics (22). Resistance to vancomycin in
organisms such as VRE is conferred by five genes, viz., vanA, vanB, vane, vanD, and vanE
which are distinguished on the basis of the level and inducibility of resistance to vancomycin
and teicoplanin (26). Acquired resistance to glycopeptides appears to be mediated by two
common classes of genes, vanA and vanB (5, 19,22,47,87, 103). The organization of vanA,
vanB, and vanD operons are very similar and it is found that the biochemical basis of
glycopeptide resistance is identical in VanA and VanB (21, 30, 36, 86).
1.4.1. VanA
VanA type resistance is the best understood, and most widely known for its genetic and
biochemical basis of resistance (70). Resistance may be induced by high levels of
glycopeptides and is therefore characterized by high level resistance to vancomycin at an
MIC of~ 64l-lg/ml and to teicoplanin at an MIC of~ 161-lg/ml (5, 15, 19,30,35,52, 70, 96,
103). The VanA enzyme is encoded by the vanA gene. This enzyme is related to the D-
Ala: D-Ala ligase that displays a broader substrate specificity and contributes to the
synthesis of dipeptides (63). The vanA gene and other genes (Figure 1.7.) involved in the
regulation and expression of vancomycin resistance are located on a transposon, Tn1546,
which often resides on a plasmid (5, 27, 30, 85). The spread of high-level glycopeptide
resistance among clinical isolates of Enterococci is through the widespread distribution of
this transposon, rather than that of a plasmid or that of a bacterial clone (52). VanA was
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found to have D-Ala : D-Ala ligase activity with an altered specificity. It produces
dipeptides different from D-Ala-D-Ala and once they are part of the carboxy terminus,
vancomycin is unable to bind to it. VanA displays a 28 - 36% amino acid identity with
two D-Ala : D-Ala ligases of E. coli which have similar catalytic properties. The reduced
catalytic efficiency shows that production of the dipeptide D-Ala-D-Ala by VanA was not
responsible for glycopeptide resistance. VanA does interfere with binding of vancomycin
to its target therefore the D-Ala: D-Ala ligase activity of VanA was not inhibited by UDP-
N-acetylmuramyl-pentapeptide (UDP-MurNAc-pentapeptide). The incubation of VanA
with UDP-MurNAc-pentapeptide alone, or in combination with D-Ala did not show signs
of cleavage or exchange of the terminal D-Ala residue therefore VanA is not a D,D-
carboxypeptidase (19). VanA produces mixed dipeptides such as D-Ala-D-Met, D-Ala-D-
Phe and D-Ala-D-Aminobutyrate more efficiently than D-Ala-D-Ala. The enzyme uses
exclusively amino acids of the D-configuration and incorporates D-Ala at the N-terminal
position. It has been concluded that synthesis of a D-Ala-X compound by VanA allows
cell wall synthesis in the presence of glycopeptides and therefore VanA does not possess
the properties that would account for resistance by modification, overproduction or
protection of the target. Ligation of the D-Ala-X with UDP-MurNAc-tripeptide would
lead to the production of peptidoglycan precursors with reduced affinities for
glycopeptides (5).
VanA was also shown to catalyze formation of ester bonds between D-Ala and D-2-
Hydroxyxacids. Preferential substrates for VanA-mediated depsipeptide and dipeptide
synthesis are D-2-Aminobutyrate which both contains an ethyl side chain. D-Ala-D-2-
Hydroxybutyrate or D-Lac which are depsipeptides produced by VanA can be added onto
UDP-MurNAc-tripeptide by the adding action present in crude extracts from susceptible
Enterococci or by the addition of purified MurF protein from E. coli (5). Substrate
specificity of VanA allows for the synthesis of peptidoglycan precursors which display
reduced affinities for vancomycin. Incorporation of D-Lac at the C-terminal ends of
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Figure 1.7. Schematic representation of the vanA gene cluster illustrating regulation of the
PR and the PH promoters (12).
VanA or vanB genes encode related proteins for reduction of pyruvate to D-Lac by VanH
or VanHs dehydrogenases, the synthesis of the depsipeptide D-Ala-D-Lac (VanA or VanB
ligase) and hydrolysis of the dipeptide D-Ala-D-Ala produced by the host Ddl (VanX or
vanXB, D-dipeptidases). VanY (VanYs) is a membrane-bound D,D-carboxypeptidase
enzyme that is also required for the VanA and VanB phenotype (15, 84).
In certain isolates where the vanA gene was mapped, some heterogeneity was seen. This
suggests that in some strains Tn1546 existed intact and in others there was insertion like
elements (27). The transposition of Tn1546 into various self-transferable plasmids and
subsequent transfer by conjugation is responsible for the spread of VanA resistance in
clinical isolates. Experimental transfer of vanA to S. aureus and other Gram-positive
organisms demonstrates the ability of these genes to be expressed in diverse hosts,
however there has not been any transfer of these genes to S. aureus in nature (64).
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1.4.2. To 1546
This transposon was originally detected on the plP816 plasmid from E. faecium BM4l47.
It consists of 10 851 bp, which is surrounded by inverted 38 bp repeats and encodes nine
polypeptides that can be assigned into four functional groups (Figure 1.8.). These are: (i)
transposition functions (OFRl and ORF2); (ii) regulation of vancomycin resistant genes
(VanR and VanS); (iii) resistance to glycopeptides by production of depsipeptides (VanH,
VanA, and VanX); and (iv) accessory proteins that may be involved in peptidoglycan
synthesis, but not necessarily involved in glycopeptide resistance (VanY and vanZ) (5,
30). The two open reading frames that are co-transcribed in the opposite direction are
thought to encode the production of putative transposase and resolvase enzymes. The
presence of the van cluster on a transposable element is a factor in the widespread
distribution of vanA - mediated glycopeptide resistance (11, 106). Heterogeneity of Tn
1546 may be due to the presence of different insertion sequences. These insertion
sequences serve as hot spots for the rearrangement of genetic fragments and may also be
associated with certain geographic locations (77). Only a single nucleotide difference in
this sequence has been documented. This suggests that the VanA transposon emerged
through a complex chain of events that occurred only once and was then transferred to
many strains. The coding sequences of the VanA transposon are strongly conserved, the
non-coding insertions are more variable. Tn 1546 also encodes a second mechanism of
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Figure 1.8. Schematic map of transposable element, Tn1546. Coding sequences are
denoted by open arrows whilst those closed and open arrows labelled IRL and IRR specify
the left and right inverted repeats of the transposon, respectively. The promoter found in
the vanS-vanH intergenic region co-transcribes vanH, vanA, and vanX (5, 76, 106).
1.4.3. VanB
The vanA and vanB clusters have been primarily found in E. faecalis and E. faecium
species and are found less commonly in other Enterococcal species. The finding of several
gram-positive species carrying vanA and a stool isolate of Streptococcus bovis carrying
vanB is evidence that there is a transfer of these genes beyond the Enterococcus genus (64,
70). Organisms exhibiting VanB phenotypes are resistant to vancomycin at an MIC of 32
- 62 I-lg/ml but are susceptible to teicoplanin (15, 27, 30, 35, 42,43,47, 58, 85). VanE is
not resistant to teicoplanin since the VanB resistance pathway is not activated by
teicoplanin because it is not an inducer of the vanB operon (42, 43, 45,54, 103). A cluster
of genes determines the VanE phenotype: VanRB-SB(Figure 1.9.). Resistance is inducible
since it might be regulated in a similar fashion to the van gene cluster (106). Determinants
reside on large mobile elements of approximately 90 - 250 kb or transposons such as
Tn1547 or Tn1549, that can be transferred from one strain of enterococci to another by
either horizontal transmission or by plasmid conjugation (27, 58, 106). The products and
expression of vanHs, -B and Xs that are regulated by a two component regulatory system
causes resistance to vancomycin (58).
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Comparison of peptidoglycan precursors from VanA and VanB strains revealed a similar
muropeptide precursor that may correspond to the D-Lac containing precursors identical to
others. The high degree of similarity between the genes involved in VanA-and VanB- type
resistance is confined to vanHB, vanB and vanXB. The distinction between the VanA and




Figure 1.9. Schematic map of the vanB gene cluster (41).
The determinants for VanA and VanB may be similar since VanA and a portion of the D-
Ala: D-Ala ligase related protein from a VanB strain displays 77% amino acid identity,
therefore, vanB encodes a ligase of altered substrate specificity (106). Vancomycin
induced production of similar D,D carboxypeptidases in both VanA and VanB strains (27).
Even though the vanB gene cluster is functionally similar to the vanA cluster it differs in its
regulation, however they rely on the same mechanism (63). VanB and VanC strains have
shown to encode ligases which determine the synthesis of altered peptidoglycan
precursors. VanB also correlates with a 39.5 kDa cytoplasmic membrane protein. The
vanB cluster contains genes that are homologous to vanH, vanA and vanX.
Billot-Klein et. al., 1990, has concluded that the constitutive expression of vancomycin
resistance of the VanB type in the absence of vancomycin does not substantially affect its
composition even though a new peptidoglycan precursor is synthesized. Thus, once
exported this precursor seems to be perfectly well recognized by the cell wall synthetic
machinery. Glycopeptide resistance by overproduction of peptidoglycan precursor that
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end in the depsipeptide D-Ala-D-Lac in susceptible Enterococci is mediated by the vanB
gene cluster. The VanRB-VanSB two component regulatory system that activates
transcription of the resistant genes in response to vancomycin but not to teicoplanin also
controls synthesis ofD-Ala-D-Lac and hydrolysis ofD-Ala-D-Lac (16).
1.4.4. Vane
The organization of the vane operon is different compared to the vanA, vanB, and vanD.
It is characterized by low-level and intrinsic resistance to vancomycin at an MIC of 4 - 32
J.!g/ml but not to teicoplanin (30, 39, 81, 84-86). Resistance is chromosomal and generally
constitutively expressed and in some strains VanC maybe inducible (30, 54, 81, 102, 106).
There are three subtypes; VanC-l, VanC-2 and VanC-3. VanC favours pentapeptide
ending in D-Alanyl-D-Serine (D-Ala-D-Ser), which weakens binding of vancomycin to the
pentapeptide (3, 13, 39, 45, 73, 81, 85, 102, 106). Higher MIC's could be explained by a
higher proportion of D-Ala-D-Ser. VanC D-Ala : D-Ser ligase, VanXYc D,D-dipeptidase
or D,D-carboxypeptidase and VanTc serine racemase which is membrane-bound mediates
glycopeptide resistance of the VanC phenotype (3, 4, 30, 39, 81, 84-86, 106). This results
in a six-fold decrease in affinity for vancomycin since the hydroxymethyl side chain of D-
Ser is thought to disrupt sterically the binding of vancomycin to the normal D-Ala-D-Ala
termini (54). These three proteins are involved in replacing the terminal D-Ala-D-Ala
precursor with D-Ala-D-Ser. VanX and VanY are enzymes that are also active with
substrates terminating in D-Ser (84, 86). VanXYc is a bifunctional enzyme since it
catalyses D,D-peptidase and D,D-carboxypeptidase activities (3, 4, 54, 83, 86).
1.4.5. VanD
In several isolates of E. faecium the less common phenotype of acquired glycopeptide
resistance includes VanD (21, 36, 64). It has constitutive resistance to moderate levels of
glycopeptides and is inhibited by vancomycin at an MIC of 64 J.!g/ml (30). They are
located on the chromosome and are not transferable by conjugation to other cocci (30).
Together with the vanA and vanB operons, the vanD operons all have similar organization
(Figure 1.10.). VanA, vanB and vanD are ligases, which synthesize D-Ala-D-Lac. It has
been shown for this phenotype precursors ending in D-Ala-D-Ala is due to a frame shift




Figure 1.10. Schematic representation of the vanD gene cluster (26).
1.4.6. VanE
Has low levels of resistance to vancomycin at an MIC of 16 ~g/ml and is susceptible to
teicoplanin (30, 34,44, 64, 85, 86). For this phenotype, the precursors normally produced
by the host are eliminated and replaced by D-Ala-D-Ser (30, 32, 44, 86).
1.4.7. VanG
VanG type resistance is acquired and is susceptible to teicoplanin at an MIC of 16 ~g/ml.
This is due to the inducible production of peptidoglycan precursors ending in D-Alanine-
D-Serine (30, 32, 34, 68, 85, 86). This cluster, which is chromosomally located, is
comprised of genes from various van operons. As in the VanC- and VanE-type strains, the
D-Ala-D-Ser ligase, VanXYG, a D,D-peptidase and a serine racemase (VanTG) are all
implicated in the synthesis of D-Ala : D-Ser. VanYG contains a frame shift mutation which
results in the premature termination of the encoded protein and accounts for the lack of
UDP-MurNAc-tetrapeptide in the cytoplasm. The transmission of VanG-type
glycopeptide resistance to E. faecalis was associated with the movement from chromosome




VanH, which has an open reading frame of 983 bp overlaps vanA by 5 bp (106). The
primary structure of the VanH protein encoded by the vanH gene is a clue to identify the
chemical nature of compounds incorporated into peptidoglycan precursors by VanA. VanH
displays a 19 - 30% amino acid identity with NAD+ -dependent dehydrogenases that
oxidize D-2-hydroxyacids to form corresponding 2-ketoacids and is located upstream from
vanA. Characterization of VanH shows that it catalyzes the opposing reaction that
produces D-2-hydroxyacid substrates for VanA. Studies have established that in the
presence of glycopeptides, VanH synthesizes a D-hydroxyacid in vivo and indicated that
incorporation of D-2-hydroxybutyrate and D-Lac into peptidoglycan precursors allows cell
wall synthesis (6, 106). It has been suggested that production of VanA and VanH, in
addition to enzymes encoded by the host chromosome may be sufficient for peptidoglycan
synthesis in the presence of glycopeptides (6). VanH which is a dehydrogenase is also
encoded by the Tn1546 transposon and is required for the synthesis of the depsipeptide D-
Ala-D-Lac by reducing pyruvate which replaces D-Ala-D-Ala in glycopeptide resistance
(9, 12, 30, 54, 103). VanH synthesizes D-Lac when pyruvate is available and efficiently
catalyzes the reduction in pyruvate and is also known as a reductase (106). This may be
seen when VanA catalyzes ester bond formation between D-Ala and D-2-hydroxyacid
products ofVanH. The resulting depsispeptides are then incorporated into UDP-muramyl-
tripetide by the D-Ala-D-Ala adding enzyme; this is unable to bind glycopeptides. Hence
VanH, VanA, and vanX encode enzymes that are essential for resistance (96).
1.4.9. VanR and VanS
Depsipeptide production is controlled by the VanS-VanR two component regulatory
system that acts as a signal-transducing system to activate transcription of genes vanA,
vanH and vanX in response to glycopeptides (5, 6, 54). This is the only two component
regulatory system controlling the expression of antibiotic resistant genes. In VanA, VanB
and VanD the vanR-vanS genes are located upstream from vanH, however it is located
downstream from vanT (30). The VanS-VanR system is the only system that controls the
expression of antibiotic resistant genes amongst two-component systems that comprise one
of the largest known families of transcriptional regulators in bacteria (6, 15, 52).
Autophosphorylation of VanS is induced by vancomycin and teicoplanin in the VanA VRE
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phenotype, whilst in the VanB phenotype it is activated by only vancomycin and VanC
does not seem to require VanS or VanR since its resistance is constitutive (54, 55)..
The two-component regulatory system consists of a sensor (VanS or VanSa) and the
regulator (VanR or VanRa) (12, 103). VanS is thought to be a membrane associated
sensor that functions to detect the early effect of vancomycin on cell wall synthesis and is
necessary for high-level transcription of vancomycin resistant genes, although it is not
required for phenotypic expression. In its primary sequence, vanS consists of two clusters
of hydrophobic amino acids which coincide with two membrane-spanning domains, hence
this gene product appears to be related to histidine protein kinases (106). Whilst VanR was
found to be a transcriptional activator necessary for the expression of vancomycin resistant
genes, hence it is known to be an activator (13, 34). In its response to its stimulation by
vancomycin, VanSa sensor histidine kinase catalyses VanRa phosphorylation thereby
switching off the resistant genes. In the absence of vancomycin, it dephosphorylates
VanRa due to the phosphatase activity of VanSs. (12, 13, 58). Since it is an activator,
phosphorylation of VanR by VanS modulates co-transcription activity (63). In addition to
their kinase activity, this system also has many histidine kinases that also act as
phosphoprotein phosphatases thereby accelerating the dephosphorylation of their similar
response regulators. Phosphatase activity plays an important role in controlling VanA type
resistance (52).
Control of transcription by VanS-VanR is involved in promoter activation (10). DNA
binding affinity at two glycopeptide inducible promoters, PR and PH, for transcription of
the regulator VanR-VanS and resistant VanHAX genes respectively are increased by
phosphorylation of VanR. Dephosphorylation of phospho-VanR is mediated by VanS.
Critical for regulation is the deletion of the vanS sensor gene that leads to constitutive
high-level transcription of the resistant gene. Mutations in the genes encoding the host Ddl
ligases and the VanSB leads to an increased resistance to glycopeptides which harbour a
wildtype vanB gene cluster (15).
The promoter PyB, which is found upstream from vanYB transcribes vanYB, -W, -HB, -B and
-XB genes and this is activated by vanRs in its phosphorylated form (12,58).
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1.4.10. VanX
VanX is a protein encoded by the vanX gene that has unknown function though insertional
activation of the vanX gene indicates that vanX is needed for resistance. vanX is not
involved in assembly steps since it is not necessary for the transcriptional activation of
vancomycin resistant genes vanH, vanA, and vanX (6). It has also been shown that VanX
is not involved in the synthesis of the 2-ketoacid substrate for the VanH dehydrogenase,
however, it may act at a later stage of cell wall assembly (9). vanX, VanXB and VanXD
are the D,D- dipeptidases that hydrolyze the D-Ala-D-Ala dipeptide which is synthesized
by the host Ddlligase and formed by the endogenous chromosomal pathway (24, 54, 103),
(12,30,52,106). Therefore vanX decreases the pool level of the normal UDP-MurNAc-
pentapeptide. It is also a metallo-protease with respect to its catalytic substrate-binding
and zinc binding sites (46,84).
1.4.11.. VanY
The VanY protein has a moderate contribution to vancomycin resistance since it is a D,D-
carboxypeptidase that cleaves the D-Ala terminal peptide (8, 33, 34). Its enzyme activity
is interconnected with the cytoplasmic membrane, whilst its production is inducible by
vancomycin (6,8, 106). VanYand vanZ are encoded by a distal part of Tn1546 and are not
necessary for glycopeptide resistance by production of depsipeptides (6, 30, 54). VanY
which is a membrane-bound carboxypeptidase that increases the level of expressed
resistance even though it is not required for resistance (24, 106). When the dipeptide D-
Ala-D-Ala, which synthesizes the pentapeptide, has escaped vanX hydrolysis, it is then
hydrolysed by VanY D, D-carboxypeptidase. For this reason VanX and VanY act together
in order to prevent the accumulation of the pentapeptide in the cytoplasm of glycopeptide-
resistant Enterococci which favours the replacement by the pentadepsipeptide in cell wall
assembly (12, 30, 103). VanY may also have D,D - carboxyesterase activity since it is




The function of vanZ is not yet understood however it contributes to teicoplanin resistance
by an unknown mechanism that does not involve the incorporation of a substituent of D-
Ala-D-Ala into peptidoglycan precursors (7, 12, 13,30).
1.5. Tolerance
Tolerance and resistance are two entirely different concepts. Those organisms that are
insensitive to antibiotics, and continue to grow in its presence are antibiotic-resistant
micro-organisms. However, organisms that stop growing but do not die in the presence of
the antibiotic are known to be antibiotic-tolerant strains (49, 67, 79, 85, 89). In both cases
infection caused by the organism continues once the therapy is stopped thus the infective
agent is not eliminated. Because of their tolerance, bacteria do not undergo active growth
since they are not killed by the normally fatal dose of antibiotic. Nonetheless, the MIC's
of tolerant strains remain identical to that of non-tolerant ones and the antibiotic binds
normally to its target (56, 89). The mechanism of tolerance is unlike that of resistance
(89). Antibiotic tolerance cannot be detected using conventional susceptibility tests seeing
as tolerant strains remain sensitive to antibiotics in an in-vitro test. Phenotypic tolerance
occurs when the bacteria respond to poor growth conditions (78). The genetic basis for
vancomycin tolerance is due to a mutation in the two-component signal transduction
system (49, 78).
The two-component regulatory system in bacteria function in controlling a variety of
responses by allowing the micro-organism to sense their environment and to respond to it
by adjusting gene expression. A specific response-regulator is paired with each sensor
kinase in the cell and this protein controls the expression of a unique group of genes.
When the sensor kinase (VncS) becomes inactivated, bacteria become tolerant, however,
were not when the response regulator (VncR) was switched 'off. The VncR response
regulator represses some of the genes required for antibiotic-induced death when the
phosphorylated mode was switched 'on'. Under normal circumstances, presence of the
antibiotic causes VncS to remove the phosphoryl group from VncR, thereby switching it
'off and allowing these genes to be expressed (49). The functional loss ofVncS may lead
29
to antibiotic tolerance becoming more easily transformed into high-level antibiotic
resistance (79).
Clinical tolerance may also occur as a result of the inactivation of the amidase gene lytA or
the down-regulation of autolysin activity (56, 78). A loss of autolysin triggering occurs in
the absence ofVncR-VncS signal transduction (78). Vancomycin is bactericidal since the
presence of the antibiotic activates autolysis which digests the cell wall exoskeleton and
kills the cells. The presence of the antibiotics in strains which have a mutation in this
signal transduction system no longer results in autolysis. Hence, tolerance leads to
substandard lysis and greatly diminished killing of the bacteria (56). The autolysins do not
rupture the cell due to differences in the cell wall or inhibition of cell wall synthesis. The
absence of autolysin action in tolerant strains could be explained by the increase in turgor
pressure and the membranes or wall becoming leaky in order to prevent turgor pressure
from dramatically increasing. Small molecules must leak out of the cell as fast as they are
pumped in to prevent the tension in the peptidoglycan layer from becoming too much. For
this reason, tolerant strains should have autolytic activity upon the increase of antibiotic
and there must be structural changes in the wall to make it more permeable (60). Growth
is inhibited in the presence of vancomycin, nevertheless the organism survives and begins
to grow when the antibiotic is removed (49, 56). Clinical isolates showing tolerance to
vancomycin is very grave as this indicates the selective pressure for the emergence of
vancomycin resistance (67, 89).
1.6. Detection
Vancomycin has become the front-line therapy for treating infections caused by
methicillin-resistant S. aureus (MRSA) and by Enterococci. The recent outbreaks of
vancomycin-resistant Enterococci with its high mortality rates re-enforces the need for
laboratories to be able to detect the various types of glycopeptide resistance (37, 54). It is
of utmost importance to determine the antimicrobial susceptibility of a clinical isolate in
order to find the best antimicrobial therapy (45, 98). Regardless of modifications made to
the criteria used to classify categories of susceptibility, the actual detection of some
vancomycin-resistant organisms in the clinical laboratory remains challenging (106). The
heterospecific expression or transfer of glycopeptide resistant genes is fast becoming a
threat among bacteria under laboratory conditions. This problem is further compounded
30
by the mobility of the vanA and vanB gene clusters by conjugation and transposition (13).
By looking at the molecular logic of the cell wall reprogramming from vancomycin-
sensitive to vancomycin-resistant bacteria one can identify new targets. The two-
component regulatory sensor kinase-response regulator pair VanS and VanR control the
structural genes vanHAX, hence these five proteins are targets for inhibition of function
and reversal of vancomycin-resistant Enterococci. Another possibility is to screen natural
products and other compound libraries for efficacy against vancomycin-resistant
Enterococci (54).
It is also recommended to speciate vancomycin resistant enterococcal isolates in order to
distinguish the VanC organisms since it has implications for the treatment and infection
control. For example, detection of low-level resistance in VanB enterococci has been
improved by modifications (27). Vancomycin resistance in clinical isolates should be
screened. This can be done by perfonning agar-screening plates which is a simple,
sensitive test. Standard susceptibility testing procedures are used to easily detect resistance
from moderate to high concentrations of vancomycin. Another method, the E-test is an
accurate alternative for detection of vancomycin resistance. Other tests such as perfonning
24-hour incubation and the use of strong transmitted light to read plates have improved the
accuracy of the disk-diffusion method (96,98).
Most laboratories can readily detect high-level vancomycin-resistant strains, yet the
problem lies in detecting low-level resistance. Laboratories are now turning to advanced
molecular biology tools to remedy this problem (l06). Genotypic detection is no longer
dependent upon phenotypic grouping. The advantages of genetic assays are that there is no
need for phenotypic expression since these can be perfonned on clinical specimens directly
(98). Techniques such as nucleic-acid based detection systems are fast becoming the key
to detect the presence of resistance genes and disseminating the elucidation of resistance
mechanisms. Research laboratories have developed genetic tests for the presence of
vancomycin-resistant genes usually based on PCR. This technique is now used because it
is a more sensitive procedure, easily accessible, simple and rapid. PCR has many
applications in medical diagnosis. It has been used in species identification of infectious
agents and specific detection of antibiotic resistant genes. PCR was used for the
simultaneous identification of species and glycopeptide resistant genotypes based on
specific detection of genes encoding D-Ala : D-Ala ligases and related glycopeptide
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enzymes (37). This technique is also now improved upon with the introduction of real-
time PCR, which is used for the quantification of expression levels of certain genes (98).
Pulse-field gel electrophoresis (PFGE) is used for individual strains of vancomycin-
resistant enterococci and the gene clusters can be analysed and tracked by DNA-based
techniques. Interesting and varied results may be seen by the molecular epidemiology of
VanA and VanB vancomycin-resistant enterococci based on PFGE (64). The detection of
mutational resistance has been made easier by rapid DNA sequence analysis and DNA
microarray technologies also look promising (98). Developing molecular techniques can
now be used to indicate the strains in which gene expression is unusual, or which contains
multiple resistant genes, or even strains with potentially novel resistance genes (106).
There is an obvious need for simple and accurate phenotypic screening and confirmation
tests for glycopeptide resistance. Recently it has been shown that low-level resistance
cannot be detected by methods such as automated susceptibility testing systems and disk-
agar diffusion. Since the emergence of vancomycin-resistant Enterococci, rapid detection,
determination and efforts in controlling outbreaks in hospitals of vancomycin resistance
may be beneficial to patients (96). Constant testing and screening for these organisms are
necessary to assess the spread of resistant organisms or resistant genes (45).
1.7. Conclusion
The rapid emergence of multi-drug resistant strains may be explained by a simple
possibility that the ability of the organism to survive the action of antibiotics appears to be
linked to the ability of the organism to acquire foreign DNA, such as resistant genes (49).
The understanding of the genetics as well as the biochemical basis of resistance have
increased through the advent of molecular typing methods of these organisms and has
given great insight into the epidemiology of these clusters. Now that vancomycin
resistance is common, synthetically modified vancomycin-group antibiotics that are
remarkably active against vancomycin-resistant Enterococci are under active development
(17). Treatment of infections caused by organisms such as enterococci is compromised by
intrinsic and acquired drug resistance. A combination of various ~-lactams with
vancomycin have shown synergistic activity against vancomycin-resistant Enterococci due
to the potential differences in the PBPs used to cross-link the vancomycin-resistant
peptidoglycan precursors.
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An important determination of the ability of an antibiotic to kill vancomycin resistant
organisms is that antibiotics have membrane anchors that bind tightly to the model surface
and hence is a significant feature (29). Other potential targets for fighting this resistance
are those enzymes involved in cell wall biosynthesis (54). By preventing the expression of
the vancomycin-resistant enzymes, the relay of responding signals can be averted. The
VanR-VanS system can be seen as the next step in chemotherapeutic intervention and
using it as a target to overcome resistance (46).
There is a longer evolutionary process in which various regulatory and structural genes are
assembled in a modular fashion. This may be due to the complexity of gene organization
and differences in gene order and the degree of similarity (41). There are diverse measures
that assist against antibiotic resistance, these are cross-resistance and co-resistance. Other
measures that are employed are the design of new in vitro resistance detection techniques
of new drugs, as well as the development of sensitive techniques for epidemiology (29).
Vigilant detection of resistant bacteria provides an essential basis for infection control
measures and antimicrobial inspection systems (98). However, true effectiveness of
prevention and treatment of these infections can only be achieved with the comprehensive
understanding of the mechanisms of vancomycin resistance (96).
1.8. Aim of the Study
The main objectives of this study were (i) to screen the S. milleri strains: P213; P35 and
B200 and the Enterococcal strains: E. faecalis 123; E. faecalis 126 and E. faecium for the
presence of vancomycin-resistance genes by means of conventional susceptibility tests; (ii)
to confirm these results with more advanced DNA-based techniques; (iii) to compare the
genotypes of these strains with their phenotypes and (iv) to study the transcription of the
resistant genes at the different stages of peptidoglycan synthesis by examining the cell wall





2.1. Bacterial Strains and Growth Conditions
The strains used in this study are listed in Table 2.1. Long term storage of cultures were
stored at -70°C in tryptone soy broth (TSB) (Biolab) supplemented with 30% glycerol.
Working cultures were subcultured fortnightly on tryptone soy agar (Biolab) plates
containing 1.4% agar per litre and stored at 4°C. Overnight starter cultures were grown in
10 ml TSB at 37°C in 5% CO2 atmosphere.
Table 2.1. Strains and their source used during this study
Strain Strain name Source
I Streptococcus milleri B200 Pietermaritzburg Pathology Lab
2 Streptococcus milleri P213 Pietermaritzburg Pathology Lab
3 Streptococcus milleri P35 Pietermaritzburg Pathology Lab
4 Enterococcus faecalis 123 Pietermaritzburg Pathology Lab
5 Enterococcus faecalis 126 Pietermaritzburg Pathology Lab
6 Enterococcus faecium Pietermaritzburg Pathology Lab
7 Enterococcus faecium BM4147* Wits Medical School Pathology Lab
8 Enterococcus faecalis ATCC* * Wits Medical School Pathology Lab
* Enterococcusfaecium BM4147 was used as a VanA control
** Enterococcusfaecalis ATCC was used as a VanB control
2.2. Micro - Titre Plate Dilution Assay
Overnight starter cultures for each strain were grown in 10 ml TSB at 37°C in 5% CO2
atmosphere. Using cation-adjusted Mueller-Hinton broth by micro-broth dilution method,
vancomycin (Sigma) susceptibility was tested at different concentrations ranging from 0
~g/ml to 160 ~g/ml. Each well contained various levels of vancomycin and a 1%
inoculum of strain in a final volume of 200 ~l. A positive control was used in which no
antibiotic was added and was inoculated with 1% culture and the negative control had no
antibiotic and was not inoculated. The 96 well micro-titre plate was incubated at 37°C in
5% CO2 atmosphere for 18 hours. The MIC for each isolate was determined at the lowest
concentration at which an isolate did not grow.
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2.3. Disk - Diffusion Assay
MIC's were determined by disk-diffusion assay. A 1% inoculum was transferred to 10 ml
sloppy agar, which is a nominally nutrient media with half the agar concentration of that
used in pour plates or spread plates. The sloppy agar was overlayed on TSA plates. Sterile
Whatman antibiotic assay disks, to which different concentrations of 0.5; 1; 2; 3; 4; 5 and
10 !-!g/ml of the antibiotic, vancomycin, had been added, were then applied to the surface
of the agar. Plates were incubated for 24 hours at 37°C in 5% CO2atmosphere. The plates
were then checked for growth and zones of inhibition around paper disks.
2.4. Lytic Curves
Overnight starter cultures of all strains listed in Table 2.1., were grown in 10ml TSB and
incubated at 37°C in an atmosphere of 5% C02. The cells were harvested by centrifugation
at 8000 x g for 5 minutes at 4°C. The bacterial pellets were washed approximately four
times in 50 mM phosphate buffer, pH 7.5. Cells were pelleted and resuspended in either 1
ml of 50 mM phosphate buffer or in lml 10 Ilg/ml of vancomycin and incubated at 37°C.
The optical density (OD) at 600 nm were measured at hourly intervals and lytic curves
constructed. A bar graph of the regression slope was constructed by working out the
regression curves from the lytic curves using the mathematical formula.
2.5. Genomic Isolation
Intact genomic DNA for all strains were isolated using the Nuc1eoSpin® C+T (Machery-
Nagel) Kit according to manufacturer's instructions. Using the support protocol for gram-
positive bacteria, 1 ml samples were prepared by centrifuging for 10 minutes at 12 000 x g
from an overnight starter culture. The supernatant was discarded and this step repeated
three times. The pellet was then resuspended in 180 III of buffer Tl. Proteinase K (30
mg/ml) was then added and the samples were vortexed vigorously. Samples were
incubated at 56°C for 3 hours until complete lysis was obtained. This step was followed by
the addition of 200 III buffer B3 to each sample, which were then vortexed and incubated
at 70°C for 10 minutes. Absolute alcohol was added to each of the samples and vortexed.
For each sample, one Nuc1eoSpin® Tissue column was placed into a 2 ml collecting tube.
The sample was applied to the column and centrifuged for 1 minute at 12 000 x g, the
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flow-through was discarded and the column placed back into the collecting tube. The
column was washed with 500 III buffer BW and centrifuged for 1 minute at 12 000 x g.
The flow-through was discarded. A second wash was performed by adding 600 III buffer
B5 and centrifuged for 1 minute at 12 000 x g and discarding the flow-through. The silica
membrane was dried and residual ethanol removed by centrifuging the column for 2
minutes at 12000 x g. DNA was eluted by placing the NucleoSpin® Tissue column into a
1.5 ml microcentrifuge tube and adding 100 III prewarmed elution buffer BE (70°C) at
room temperature for 1 minute. Tubes were centrifuged for 1 minute at 12 000 x g and
DNA collected in the collecting tube. Samples were stored at -20c C until required.
2.5.1. Quantitation of DNA
The genomic DNA obtained was quantified to measure the quality of the DNA using the
GeneQuant pro RNA/DNA calculator (Pharmacia). DNA samples were diluted a 100
times in BE buffer. Absorbance measurements were determined at A260 and A28o. This was
used to calculate the A26o/A28o ratio of the DNA sample.
2.5.2. Detection and Analysis of Extracted DNA by Agarose Gel Electrophoresis
Extracted DNA was analysed via agarose gel electrophoresis on a 0.8% (w/v) agarose gel,
prepared in 1 x TAE (4.846 g of Tris, 0.41 g of anhydrous sodium acetate, and 0.372 g
EDTA, pH 7.8) buffer. The gel was stained with 2.5 f.ll of ethidium bromide stock solution
(10 mg/ml) to give a final concentration of 0.5f.lg/ml of ethidium bromide. The DNA
samples (10 f.ll) were added to 2 f.ll of loading dye and then loaded into separate wells.
Electrophoresis was initially carried out at a 100 volts for 5 minutes and then adjusted to 80
volts for 90 minutes at maximum current. The presence of DNA was verified using a DV
transilluminator.
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2.6. Polymerase Chain Reaction (PCR)
2.6.1. PCR Primers
Oligonucleotide primers were synthesized according to Miele et al., 1995 (Table 2.2.) and
Dukta-Malen et al., 1995 (Table 2.3.) at the University of Cape Town, Department of
Biochemistry. The sequences and properties of the primers are listed in Table 2.2.
Table 2.2. Properties and nucleotide sequences of PCR primers for vanA, vanB and vane



















Ta = annealing temperature
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Table 2.3. Properties and nucleotide sequences of PCR primers for vanA, vanE and vane
associated genes according to Dukta-Malen et aI., 1995













2.6.2. DNA Amplification by peR
Isolated genomic DNA of each strain was used as a template. Taq Polymerase (Roche)
was used as the amplifying enzyme. The PCR reaction mixtures were constituted as
outlined in Table 2.4.
. .....~.
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Table 2.4. Reaction mixtures used for the PCR amplification of DNA target sequences of
vanA, vanB and vane
Reagent Initial cone. Required cone. Volume (J!l)
Template DNA 0.5 J!g 2
Sterile distilled water 15.45
10 X PCR reaction buffer lOx 1 x 2.5
with MgCh
dNTP 10mM 500 j.lM 1.25
Primer (Forward) 7.5 J!M 0.5 j.lM 1.7
Primer (Reverse) 7.5 J!M 0.5 J!M 1.7
Taq 5 U/J!l 2U 0.4
Total 25
A negative control was also prepared together with the other reaction mixtures in which the
template DNA was substituted with sterile distilled water. PCR amplifications were
carried out in an automated thermal cycler (Perkin-Elmer Applied Biosystem GeneAmp
PCR system 9700, Norwalk, USA). The PCR parameters for primers in Table 2 consisted
of an initial denaturation at 94°C for 3 minutes; this was followed by 30 cycles of DNA
denaturation at 94°C for 30 seconds; primer annealing at the appropriate temperature
(Table 2.2) for each set of primers for 2 minutes; and DNA extension at 72°C for 2
minutes. After the last cycle, a final extension at 72°C for 6 minutes was performed and
the reaction mixtures were stored at 4°C.
The PCR parameters for primers in Table 2.3. consisted of an initial denaturation at 94°C
for 2 minutes; this was followed by 30 cycles of DNA denaturation at 94°C for 1 minute;
primer annealing at 54°C for each set of primers for 1 minute; and DNA extension at noc
for 1 minute. After the last cycle, a final extension at 72°C for 5 minutes was performed
and the reaction mixtures were stored at 4°C.
The PCR products were analysed by electrophoresis in 1 x TAE buffer on a 1.5% (w/v)
agarose gel. The gel was stained with 10 mg/ml stock solution of ethidium bromide to a
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final concentration of 0.5 flg/ml. Molecular weight marker III (Roche) was used as a
standard marker to confirm the approximate size of the amplified DNA.
2.7. Southern BlotlHybridisation
2.7.1. Transfer of DNA
The VacuGene XL Protocol No. 1 (Pharmacia) was used to transfer DNA onto nitrocellulose
membrane of 110 x 70 mm in size. The nitrocellulose membrane was pre-treated prior to
transfer with sterile distilled water for 1 minute and 20 x SSC for 10 minutes. Genomic
DNA of the bacterial strains was resolved by electrophoresis on a 0.8% agarose gel. The gel
was subjected to depurination, denaturation and neutralization for 20 minutes each on a
VacuGene XL apparatus. DNA from the gel was transferred onto the nitrocellulose
membrane with transfer solution (20 x SSC) for 60 minutes. Following transfer the wells
were clearly marked, and the gel removed. The nitrocellulose membrane was washed in 2 x
SSC for 5 minutes to wash away debris. The filter was then air dried for 30 minutes, baked at
80°C for 2 hours and stored at room temperature until required.
2.7.2. Oligonucleotide Tailing With DIG-dUTP dATP
The Roche 3' end tailing kit was used to label oligonucleotide probes. The probe used was
the primers of vanA j , vanB j and vane l , respectively. The tailing reaction was constituted
by adding the following solutions to a sterile microcentrifuge tube: (i) 4 /-LI of 5 x reaction
buffer (l M Potassium cacodylate, 0.125 M Tris-CI, 125 mg/ml BSA pH 6.6); (ii) 4 /-LI of
25mM CoCI2; (iii) 1 /-LI DIG-dUTP solution; (iv) 1 III (50 U) terminal transferase; (v) 0.2 /-LI
probe (lOO pmoles) and 9.8 /-LI sterile distilled water. The solutions were mixed and
incubated at 37°C for 30 minutes, thereafter placed on ice. A 100 fll Hybridization solution
(6 x SSC, 0.5% SDS and 5 x Denhardt's solution) was added to the tailing reaction and
stored at -20°C for use in hybridization experiments.
2.7.3. Pre-Hybridization and Hybridization
The blotted membrane was placed in a hybridization tube containing 10 ml of pre-
hybridization solution and pre-hybridized for 3 hours at 37°C. The probe was then added to
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hybridization solution and mixed. The pre-hybridization solution was decanted and the
probe/hybridization solution was added to the tube. The membrane was hybridized
overnight at 37°C. After hybridization the membrane was washed twice in 2 x SSC, 0.1 %
SDS for 15 minutes each and then twice in 0.1 x SSC, 0.1% SDS, for 15 minutes each. The
membrane was allowed to air dry and stored for the detection step.
2.7.4. DIG Nucleic Acid Detection
Detection was performed using the DIG-detection Kit (Roche) according to manufacturer's
instruction. The membrane was washed in buffer 1 (0.1 M Tris-Cl, pH 7.5; 0.15 M NaCl)
for 1 minute. The membrane was blocked using freshly prepared Buffer 2 (1 % skim milk
powder in 100 ml Buffer 1) at room temperature for 30 minutes with continuous shaking.
After blocking, the membrane was washed briefly in Buffer 1. Anti-digoxigenin-AP
conjugate was diluted into Buffer 2 to a final concentration of 150 mU/ml and the membrane
was incubated in 20 ml of this solution for 30 minutes. The membrane was thereafter
washed in Buffer 1 twice for 15 minutes, to remove any unbound antibody conjugate. This
was then equilibrated in 20 ml of Buffer 3 (0.1 M Tris-Cl, pH 9.5; 0.1 M NaCl; 50 mM
MgCh) for 2 minutes. Freshly prepared colour substrate solution (200 ~l NBTIBCIP
solution in 10 ml Buffer 3) was made and the membrane incubated in colour substrate
solution in the dark. A colour precipitate develops and when desired bands were detected,
the membrane was washed in 1 x TE, pH 8.0, to stop the reaction.
2.8. Analysis of Peptidoglycan Precursors
Extraction and analysis of peptidoglycan precursors was performed as described by
Baptista et al., 1997. A 1% inoculation of the respective bacterial strain in TSB
supplemented with 0.5% yeast extract was grown to the mid exponential phase (OD6oo =
1), 20 ~g/ml vancomycin of2 x the MIC for each of the uncharacterized strains were used
to accumulate peptidoglycan precursors at the transglycosylation and transpeptidation
stage of biosynthesis. Bacitracin (100 ~g/ml) was also used to arrest peptidoglycan
synthesis at the transpeptidation stage. Incubation was continued for 30 minutes and
bacterial cells were harvested by centrifugation at 11 000 x g for 10 minutes at 4°C, and
treated with 7% trichloroacetic acid (TCA) for 15 minutes at O°C in a final volume of2 m!.
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The extract was centrifuged at 46 000 x g for 10 minutes at 4°C, and the supematant
fraction containing the cytoplasmic peptidoglycan was collected.
TCA was neutralized by the addition of 0.11 g solid sodium bicarbonate, and salt was
removed from the extract by gel filtration on a Sephadex G10 (Sigma) column (20 x 1.5
cm). The elute was monitored at 252 nm and cell wall precursors eluted immediately after
the void volume of the column. Fractions (100 Ill) containing the cell wall precursors were
analyzed by high-performance liquid chromatography (HPLC) and applied to a C-18
reverse-phase column of 250mm by 4.6 mm (ODS-Hypersil, 5 IlM; Thermo Hypersil-
Keystone). 0.05 M ammonium acetate (pH 5.03) was used as the mobile phase at a flow
rate of 0.2 ml/min with the application of a methanol gradient (0 - 25%) in the same buffer
from 5 to 45 minutes. The elution times for the precursors were approximately: UDP-
MurNAc-tripeptide, 7.7 minutes; UDP-MurNAc-tetrapeptide, 16 minutes; UDP-MurNAc-
pentapeptide, 25 minutes and UDP-MurNAc-pentadepsipeptide, 42 minutes. The relative
proportions of these four precursors were determined from the integrated peak areas, and
the results were expressed as percentages.
2.9. Mass Spectrometry
Analysis of peptidoglycan precursor peaks collected during HPLC from the various
precursors of various strains were analysed by mass spectrometry on an API ill quadruple
mass spectrometer equipped with an IonSpray source (Sciex, Thornhill, Canada), at the
University of Stellenbosch (South Africa).
2.10. DNA Sequencing
Automated DNA sequencing utilizes fluorescent tracers instead of radioisotopes to detect the
DNA, thereby eliminating or significantly reducing the use of radioactive materials in some
research laboratories.
2.10.1. Big Dye Terminator v3.0 Ready Reaction Cycle Sequencing
The first step of the DNA sequencing procedure involved a PCR Cycle using the GeneAmp
PCR System 2700. The following reaction components used for PCR were added to a sterile
PCR tube as follows: (i) 400 ng of DNA; (ii) 5 x Big Dye terminator v3.l buffer (3 Ill); (iii)
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7.5~M primer; (iv) Big Dye Terminator v3.1 cycle sequencing ready reaction mix-lOO (2 ~l)
and sterile distilled water (12.01 ~l) to give a total volume of 20 ~l reaction. The PCR
profile used was as follows: 96°C for 10 seconds, 55°C for 30 seconds, 60°C for 4 seconds
and for 35 cycles. The reaction tube was immediately removed and samples used for
purification of extension product.
2.10.2. Purification of Extension Products
For each sequencing reaction a sterile 1.5 ml microcentrifuge tube with the DNA
extraction number, PCR primers used, and date of sequencing reaction is labelled. To each
tube 50 ~l of 100% ethanol was added, 2 ~l of 125 mM EDTA (Ethylene diamine trifluro
acetate) and 2 ~l of 3 M NaAc (sodium acetate, pH 4.6-5.2). The entire 20 ~l of the DNA
sequencing reaction was added to the tube and vortexed gently for a few seconds. The
tubes were placed at 4°C for 20 minutes to precipitate sequencing reaction extension
products. The tubes were placed in a microcentrifuge and spun for 20 minutes at
maximum speed. The supematant was carefully removed, and the pellet washed by
resuspending the pellet with 120 ~l of 100% ethanol by pipetting up and down. This was
vortexed briefly. Samples were centrifuged for 15 minutes at maximum speed and all
traces of supematant removed. The pellet was washed using 100% ethanol. Samples were
dried in a laminar flow hood for 20 minutes.
2.10.3. Sequencing of Extension Products
The resulting sequencing reaction was loaded onto a 96 well optical reaction plate and
placed into a Genetic Analyzer 3100 (Applied Biosystems). The reaction was run for 4





The increasing amount of the reported incidences of outbreaks of vancomycin resistance
has highlighted that there is a call for laboratories to efficiently and accurately detect the
various types of resistance (27, 38). The first line of defence against the spread of
vancomycin resistant organisms, is the laboratory (27). Simple and accurate phenotypic
screening methods need to be in place together with confirmatory tests to identify
resistance. These tests will entail the elucidation of the molecular and biochemical
mechanisms of resistance (96). However, the detection of some vancomycin-resistant
organisms in the laboratory still prove to be difficult since those with lower levels of
resistance are less easily detectable compared to that of high level resistance which are
more readily detected (106).
3.1. Micro - Titre Plate Dilution Assay
In vitro susceptibility tests are performed on those micro-organIsms that are suspected to
be responsible for diseases and that may have resistance to antimicrobial agents (40).
Standard susceptibility testing protocols are able to detect resistance from moderate to high
concentrations of vancomycin (50). The traditional method of determining the MIC of
strains is agar or broth dilution. The National Committee for Clinical Laboratory
Standards (NCCLS) has recognized broth micro-dilution in cation-adjusted Mueller-Hinton
broth and some studies have used it as the reference method instead of agar dilution (27,
40, 106). Mueller-Hinton is the medium of choice since it allows for good growth and is a
low antagonist (40).
Broth dilutions monitor the micro-organisms capability to produce visible growth on a
series containing dilutions of the antibiotic. The MIC of the micro-organism to an
antibiotic is the lowest concentration of the antibiotic which prevents the appearance of
visible growth within a specified time (40).
The typical vancomycin MICs for varIOUS species of Enterococci established by the
NCCLS are> 128 Jlg/ml for isolates that typically contain the vanA gene and are therefore
classified as the VanA phenotype. The VanB phenotype would have an MIC of 16 - 64
Jlg/ml of vancomycin whilst the VanC phenotype would typically produce vancomycin
MICs of 2 - 16 Jlg/ml (27).
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As determined by micro-titre broth dilution and in accordance to the NCCLS, the
following MICs to vancomycin for the strains tested are represented by the bar chart in
Figure 3.1. All the strains, S. milleri P213, S. milleri P35, S. milleri B200, E.faecalis 123
and 126, E. faecium, and the VanA control appear to have MICs above 64 Ilg/ml and hence
are considered to be of the VanA phenotype. The VanB control was correctly identified as
a VanB phenotype since it had an MIC of 61 Ilg/m.
The high MIC value obtained for all strains, including that of the VanB control could be
because of the amount of the peptidoglycan precursor, D-Ala-D-Lac present. Hence these
bacterial strains are resistant to vancomycin at such a high value because of the high






















S.millP213 S.mi1lP35 S.millB200 EJae123 EJae126 E.faeci VanA Con VanB Con
Bacterial Strain
Figure 3.1. Bar chart showing the MIC's of each strain via micro-tire plate dilution assay.
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3.2. Disk - Diffusion Assay
The vancomycin resistance level was confirmed by disk-diffusion assay since it has been
effective in detecting intrinsically resistant gram-positive organisms, especially those that
are highly resistant (106). Agar screening for the detection of the resistance phenotypes by
means of disk-diffusion and agar dilution seem to be the most dependable and
straightforward method (27). The accuracy of this method is improved by incubating the
plate for 24 hours and reading the plate using strong transmitted light (50).
The MIC was the lowest concentration of antibiotic which did not allow for growth (75).
Upon examination of plates under transmitted light, circular zones of inhibition around the
disk could be seen. The antibiotic was responsible for the appearance of this zone and the
diameter of each zone was measured. The zones of all the strains varied between 8 - 14
mm in size. In 1991, the NCCLS introduced its zone diameter and MIC testing
interpretive approved standards for susceptibility testing. The interpretive standards for
susceptible and resistant Enterococcal strains are zone diameters of ~ 17 mm and that of S;
14 mm respectively (l06). Hence, these strains were found to be resistant to vancomycin.
The MIC's of each strain by the disk-diffusion method are found in Table 3.1. This table
also indicates their phenotype according to their corresponding MIC value and NCCLS
susceptibility testing standards. This phenotypic susceptibility test identified strains 1- 6 as
VanC phenotypes whereas in the previous test by micro-dilution these strains were
characterized as VanA phenotypes. However, even though the MIC of the VanA control
was lower than that of micro-dilution, it is still correctly identified as a VanA phenotype
since its value is equal to 64f.!g/ml, which is characteristic of the VanA class resistance.
The VanB phenotype also showed a lower MIC value compared to that in broth micro-
dilution, however this value still lies between 16 - 64 f.!g/ml and is still therefore correctly
classified as a VanB phenotype. Since the control strains were accurately identified, the
MIC values of the other bacterial strains could be recognized as that of the proposed VanC
phenotype. It is thought that the balance between normal and abnormal peptidoglycan
synthesis is responsible for the level of resistance expressed. Hence this low MIC obtained
for the strains can be explained by the amount D-Ala-D-Ser present (27).
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The reason for the lower MIC values obtained during the disk-diffusion susceptibility test
could be accounted for the fact that these strains are allowed to grow for 24 hours on agar,
whereas, in broth micro-dilution they are grown in cation adjusted Mueller-Hinton broth.
Mueller-Hinton broth facilitates the fastidious growth of these organisms and hence the
rate of growth is much higher in 18 hours than that of agar, even though it was incubated
for 24 hours. Agar plates require sufficient incubation time for the expression of resistant
determinants in order for a substantial amount of growth to be visible (96). Another reason
is that even though a 1% inoculum was used for both tests the final volumes in which they
were incubated were different. For the micro-titre plate the MICs were assessed in a
smaller volume compared to an agar plate.
The discrepancy in MIC obtained from the various susceptibility tests could also be
attributed to the heterogenous population of cells in a bacterial strain. This factor accounts
for the difference and irreproducibility of these quantitative methods of detection (96).
There are other methods that aid in the accurate detection of these genes, a valuable
technique used is that ofPCR (38).
Table 3.1. The MIC values of vancomycin against each strain obtained via disk-diffusion
No Strain MIC (~g/ml) Phenotype
1 Streptococcus milleri B200 5- 10 VanC
2 Streptococcus milleri P213 5 -10 VanC
3 Streptococcus milleri P35 5 -10 VanC
4 Enterococcus faecalis 123 5 -10 VanC
5 Enterococcus faecalis 126 5 -10 VanC
6 Enterococcus faecium 5 -10 VanC
7 Enterococcus faecium BM4147 >64 VanA
8 Enterococcus faecalis ATCC 32 VanB
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3.3. Lytic Curves
This method was used to determine the sensitivity of the strains to vancomycin, which is a
cell wall synthesis inhibitor. Vancomycin is also thought to be a secondary autolytic-
inducing antimicrobial agent in clinical settings (89). Autolytic enzymes are responsible
for the bactericidal activity of those antibiotics that interrupt cell wall synthesis (67). The
antibiotic then triggers these enzymes to digest the cell wall exoskeleton. Autolysis of all
strains was also observed in phosphate buffer, pH 7.5. This was used as the untreated
growth control since it is a nutrient free substrate. Data was represented as a percentage of
the absorbance at 600nm relative to that at time zero for each sample. The rate of autolysis
was measured by the decrease in the percentage optical density at 600nm. A decrease in
the percentage OD6oo, shows an increase in autolytic activity.
Autolytic-induced lysis of S. milleri P213 is depicted in Figure 3.2. The rate of autolysis
for this strain appeared to be much higher in phosphate buffer than under induced
conditions with vancomycin. There was a much more rapid decrease in the percentage OD
under uninduced conditions. This strain seemed to avoid the lysis-inducing effect of
vancomYCIn at an early stage. Hence vancomycin in this case had low autolytic
capabilities. Therefore there must be a resistant mechanism present, which allows for the
growth of the strain in the presence of the antibiotic. This organism may be avoiding cell
death by modifying the drug's peptide target to a depsipeptide such as D-Ala-D-Lac
instead of the normal D-Ala-D-Ala and allows peptidoglycan polymerisation to occur in
the presence of the antibiotic (64, 65). The presence of vancomycin is required by some
bacterial cells that are resistant in order to grow and depend on the alternate D-Ala-D-Lac
pathway since these cells do not have the normal D-Ala-D-Ala pathways. However, the D-
Ala-D-Lac pathways are only activated in the presence of this antibiotic (14). The rate of
autolysis was also much higher in phosphate buffer than in vancomycin for E. faecalis 123
shown in Figure 3.6. In Figure 3.7., E. faecalis 126 exhibited an increase in autolysis in
phosphate buffer, though the rate was very similar under induced conditions. These
patterns indicate that lysis induced by vancomycin does not appear to have a negative
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Figure 3.2. Vancomycin induced autolysis assay of S. milleri P213. Strain in phosphate
buffer served as a control of autolysis.
Figure 3.3. shows autolytic-induced lysis of S. milleri B200. Initially a rapid decrease in
OD was seen for cells under uninduced lysis, however, a higher rate of autolysis was
observed for S. milleri B200 under induced conditions in the presence of vancomycin.
This indicates that eventually vancomycin does induce lysis of these cells. Therefore,
after a while cells are much more susceptible to the action of this antibiotic even though
initially it displayed some sort of resistance to it. Other strains such as E. faecium, Figure
3.5.; the VanA control, Figure 3.8.; and the VanB control, Figure 3.9., showed similar
kinetics of autolysis. None of these strains seem to afford any protection to the
vancomycin challenge.
However, all strains, if they are resistant, as confrrmed by the MICs obtained from disk-
diffusion should show patterns of autolysis whereby autolysis occur at a higher rate in
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Figure 3.3. Vancomycin induced autolysis assay of S. milleri B200. Strain in phosphate
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Figure 3.4. Vancomycin induced autolysis assay of S. milleri P35. Strain in phosphate
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Figure 3.5. Vancomycin induced autolysis assay of E. faecium. Strain in phosphate
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Figure 3.6. Vancomycin induced autolysis assay of E. faecalis 123. Strain in phosphate




















Figure 3.7. Vancomycin induced autolysis assay of E. faecalis 126. Strain in phosphate

















Figure 3.8. Vancomycin induced autolysis assay of VanA Control. Strain in phosphate

















Figure 3.9. Vancomycin induced autolysis assay of VanB Control. Strain in phosphate
buffer served as a control of autolysis.
A regression curve (Figure 3.10.) was then obtained for all strains to compare the autolysis
under normal and induced conditions. An increased regression slope is indicative of a
higher rate of autolytic activity. Only S. milleri P213 and E. faecalis 123 seemed to have
higher autolysis under normal conditions than under vancomycin-induced conditions. S.
milleri P35 and E. faecalis 126 showed the exact same rate of autolysis, under both normal
and induced conditions. This implies that vancomycin did not have any effect on these
cells because it did not affect the normal autolytic pathway. However, vancomycin did


















Figure 3.10. Regression slopes indicating the rate of autolysis for all strains under normal
conditions in phosphate buffer and under autolytic-induced conditions in 10 Jlg/ml
vancomycin.
3.4. Genomic DNA Isolation
DNA isolated for each bacterial strain using the NucleoSpin® Kit was run on a 0.8 %
(w/v) agarose gel to verify that chromosomal DNA, was, in fact present, and to ensure that
. there was no RNA contamination. Figure 3.11. shows that DNA was successfully isolated
and that no RNA contamination occurred during the procedure. The bright bands observed
in this figure indicate that the concentration of the DNA obtained was high. This quality of
the DNA obtained was confirmed by the absorbance readings in which the A26o/A28o ratio
was between 1.8 and 2, which indicated that the DNA obtained were of pure content. The
DNA isolated was then used as a template in the subsequent peR reactions.
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Figure 3.11. An agarose gel of 0.8% (w/v) showing DNA isolated. Lane 1: S. milleri
P213; Lane 2: S. milleri P35; Lane 3: S. milleri B200; Lane 4: E. faecalis 123; Lane 5: E.
faecalis 126; Lane 6: E. faecium; Lane 7: VanA Control; Lane 8: VanB control.
3.5. Polymerase Chain Reaction (PCR)
Because of the rapidly increasing progress of technology, techniques such as PCR have
been used in various applications, including in the medical field for diagnosis of certain
infectious agents. This molecular technique can now be used in the detection of
vancomycin-resistance genes, either that, of acquired or intrinsic. It is a more rapid and
sensitive technique compared to that of phenotypic identification by traditional
susceptibility testing or DNA-DNA hybridization. It is also more readily available and is
especially used more so to detect low-levels of vancomycin resistance (38, 45, 106). PCR
is a much more reliable method since it can be applied directly to clinical samples and can
also be used on purified DNA (70).
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In this study, this advanced molecular biology tool was used parallel to phenotypic
susceptibility tests.
3.5.1. Using Primers From Miele et al., 1995
These primer sets were initially used to detect the vancomycin resistant genes for the
different phenotypes. To establish the specificities of these primers that would reliably
correlate the genotypes of vancomycin resistance with their respective phenotypes, a
BLAST search was performed on the oligonucleotide sequences. These sequences were
homologous to published nucleotides sequences.
In Figure 3.12., PCR products were obtained using the VanA primer pair. These results
show that there is amplification in lanes 1 - 5. This primer pair targeting the vanA gene
cluster yielded products of approximately the appropriate size of 1029 bp, hence these strains
seem to have the vanA genes and are of this phenotype. This correlates with the MIC values
obtained by micro-titre plate dilution. There also seems to be multiple amplicons between
1375 and ~ 564 bp. Hence, this PCR reaction needed to be optimised. Negative controls, in
lanes 6 and 7, without Taq polymerase and without DNA template, respectively, were also
included in the PCR reaction to check for false positive results. No bands were seen in these
lanes, therefore no amplification occurred. This implies that the amplification obtained in
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Figure 3.12. Image of PCR Products amplified with Primer VanA. Lane M: Molecular
Weight Marker Ill; Lane 1: S. milleri P213; Lane2: S. milleri B200; Lane3: S. milleri P35;
Lane 4: E. faecalis 123; Lane 5: E. faecalis 126; Lane 6: Negative Control (No Taq); Lane
7: Negative Control (No DNA).
PCR optimisation entails increasing the stringency of the reaction. This could be done
either by varying the magnesium chloride concentration or the annealing temperature. In
Figure 3.13. optimisation was done by using a magnesium concentration of 1.5 mM,
whilst all other reagents and variables were kept constant. In this reaction, VanA and
VanB controls were also included since these strains are PCR analysed strains. These were
also used to assess the ability of these primers to identify vancomycin resistance in the
strains used in this study. These positive controls are critical in a PCR reaction in order to
check for false negative results (98).
In this figure, multiple amplification was again observed for every strain. The PCR
products obtained were estimated to be between 900 - 400 bp. The expected SIze,
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however, was supposed to be that of 1029bp. Lane 7 was the VanA control. Even though









Figure 3.13. PCR products obtained with Primer VanA at an [MgCh] of 1.5 mM.
Lane: M, Molecular Weight Marker III; Lane 1: S. milleri P213; Lane 2: S. milleri
8200; Lane 3: S. milleri P35; Lane 4: E.faecalis 123; Lane 5: E.faecalis 126; Lane 6:
Efaecium; Lane 7: VanA Control; Lane 8: VanB Control; Lane 9: Negative Control
(No DNA).
The DNA template of each strain was used for amplification with the VanB primer.
Figure 3.14. shows clearly amplification in each lane. Amplification obtained was of the
correct size since the expected product at 457 bp was seen. However, other bands can also
be seen. This suggests that the reaction was not entirely specific and the magnesium
chloride concentration and annealing temperature needed to be adjusted to more stringent
conditions. No bands can be seen for the negative controls, which indicates no random
DNA was amplified and none of the buffers contained any contamination. Even though
products of the correct sizes were observed, this did not correlate with the MIC values
obtained in both, micro-titre plate dilution or disk-diffusion.
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Figure 3.14. Gel imaging showing isolates amplified with Primer VanB. Lane: M,
Molecular Weight Marker Ill; Lane 1: S. milleri P213; Lane 2: S. milleri B200; Lane 3: S.
milleri P35; Lane 4: E. faecalis 123; Lane 5: E. faecalis 126; Lane 6: Negative Control (No
Taq); Lane 7: Negative Control (No DNA).
Another PCR reaction was also performed in which the DNA of each strain was amplified
with the VanC primers. Amplification was only observed in lanes 1 and 2, for S. milleri
P213 and B200, respectively. The expected size of the PCR product was 811 bp. In
Figure 3.15., one of the multiple bands in lane 2 corresponded to that size. S. milleri B200
could perhaps be of the VanC phenotype, however, this strain also had amplification with
the other two primer sets. The results obtained from this PCR reaction, and those
performed under stringent, or optimised conditions appeared to have varying results. Even
though controls were added to the PCR reactions, the phenotype of these strains still
remained unclear.
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Figure 3.15. Image of DNA amplified with Primer VanC. Lane: M, Molecular Weight
Marker Ill; Lane 1: S. milleri P213; Lane 2: S. milleri B200; Lane 3 S. milleri P35; Lane 4:
E. faecalis 123; Lane5: E. faecalis 126; Lane 6: Negative Control (No Taq); Lane 7:
Negative Control (No DNA).
Since no definite conclusions could be made as to which resistant phenotype each bacterial
strain represents, sequencing was performed on those amplicons. The amplified products
obtained via PCR of S. milleri B200 and P213, amplified with Primer VanA respectively,
were then used for DNA sequencing.
3.6. Sequencing of peR Products Generated By Amplification With Miele et al., 1995
Primers
The specificity of the amplicons obtained from PCR was confirmed by DNA sequencing.
The sequencing results obtained are shown in Figures 3.16. and 3.17. for S. milleri B200
and Figures 3.18. - 3.20. for S. milleri P213. The sequences obtained in these figures
were subjected to a BLAST search. S. milleri B200 was found to be homologous to a
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pGEM vector system, whilst S. milleri P213 showed homology to a Mus musculus BAC
clone. These results were found to be totally unrelated to any of the vancomycin resistance
genes tested, since these do not contain vancomycin resistance genes.
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TA G GGCGAATTCGA GCT CG GTACCC G G GG ATCCT C TAG AG TCGA CN T C CAG G CATG CA AG CT TG AG T ATT CT AT AG TGT CAC C T AA AT AN C T TGG CG T AAT CATGG T CAT AG
10 20 30 40 ~O 60 70 80 90 lOO 110
Figure 3.16. DNA sequencing results of S. milleri B200 amplified with Primer VanA from Miele et al., 1995.
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T TCG GTG TAG G TCG TT CGC TCC AAGC TGGG CTG TGTG CACG AACCCC CCG TT CAGC CCG A CCGC TG CGCCTT ATCCGG T AACTA TCG T C TTG AGT CCAA CCC GG T AAG A
730 740 750 760 770 780 790 800 810 820 830
TG MAAAA TTGG CTG ANG TTNC ATGN T TAN CK;NGNGGCN CT TCCCNCGATTTG CNNTTN<G TCNNC AAA lGGCGGACCCCCN CGGGAAAAAA
1240 1250 1260 1270 1280 1290 1300 1310 1320
Figure 3.17. DNA sequencing results of S. milleri B200 amplified with Primer VanA from Miele et al., 1995.
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Figure 3.18, DNA sequencing results of S. milleri P213 amplified with Primer VanA using Miele et al., 1995 Primers.
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Figure 3.19. DNA sequencing results of S. milleri P213 amplified with Primer VanA using Miele et al., 1995 Primers.
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Figure 3.20. DNA sequencing results of S. milleri P213 amplified with Primer VanA using Miele et al., 1995 Primers.
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3.7. Southern Blot Hybridization Using Miele et ai, 1995 Primers as Probes
Southern blotting is another approach using probes for the vancomycin genes, which is
being applied for the determination and detection of vancomycin phenotypes. Seeing as
how the PCR reactions yielded uncertain results and the sequencing produced much
unrelated matches, the primer sets were then used as probes for southern blot hybridisation.
Southern blotting is performed to confirm whether the gene sequences for vancomycin
resistance is present in these strains. The reason why the primers for PCR are used as
probes is to check whether they are compatible with the DNA since no conclusive results
were obtained from neither the different PCR reactions nor the sequencing results.
Another reason could be that the gene sequences could be present in these strains but were
not detected.
Figure 3.21. is the southern blot obtained using primer VanA as a probe. From this figure
only the DIG-labelled Molecular Weight Marker could be seen. This indicates that the
detection worked; however, no other bands were seen. This implies that the probes did not
hybridise to the DNA sequence, hence these primers are not specific enough to detect
whether vancomycin resistant genes are present. The VanA primer as a probe did not even
detect the vancomycin resistant gene sequence in the VanA control, which is already
confirmed as a vancomycin resistant phenotype. pJF 5.5 was used as a negative control
since it is a recombinant vector and does not code for vancomycin resistance. This control
did not appear on the blot as expected.
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Figure 3.21. Southern blot hybridisation of PCR amplicons using Primer VanA (Miele et
al., 1995) as a probe. Lane M: Dig-labelled Molecular Weight Marker; Lane 1: S. milleri
P213; S. milleri B200; Lane 3: Efaecalis 123; Lane 4: Efaecalis 126; Lane 5: Efaecium;
Lane 6: VanA Control; Lane 7: Negative control (pJF 5.5 DNA).
Primer VanB was also used as a probe in another southern blotlhybridisation experiment.
The results obtained may be seen in Figure 3.22. Again, in this blot only the DIG-labelled
Molecular Weight Marker was detected. However, no other bands can be seen, hence
nothing else was detected, not even the VanB control which contains the gene sequence for
the VanB resistant phenotype. Hence, this primer was also not specific enough to detect
the presence of vancomycin resistance. The negative control used in this blot was also pJF
5.5, which does not contain genes for VanB type resistance. No false negatives were
observed.
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Figure 3.22. Southern blot using Primer VanB (Miele et al., 1995) as a probe. Lane M:
Dig-labelled Molecular Weight Marker; Lane 1: S. milleri P213; S. milleri B200; Lane 3:
E. faecalis 123; Lane 4: E. faecalis 126; Lane 5: E. faecium; Lane 6: VanB Control; Lane
7: Negative control (pJF 5.5 DNA).
Figure 3.23 is a southern blotlhybridisation result of all strains using the VanC set of
primers as a probe. From this figure, it can be seen that only the DIG-labelled Molecular
Weight Marker was detected. No other bands were observed in any of the lanes. This
suggests that none of the strains, including the negative control, pJF 5.5, does not contain
the VanC sequence.
The southern blotlhybridisation experiments performed using each of the primer pairs as
probes did not yield any results. Hence, the results obtained using this method, together
with PCR and sequencing, were not conclusive enough to determine the phenotype of each
of the strains. This also meant that the primers used were not specific enough to detect the
various vancomycin resistant phenotypes.
Another reason why these primers might not be specific enough was that the properties of
the oligonucleotide sequences were based on that of their ligases.
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Figure 3.23. Southern blot using Primer VanC (Miele et al., 1995) as a probe. Lane M:
Dig-labelled Molecular Weight Marker; Lane 1: S. milleri P213; S. milleri B200; Lane 3:
E. faecalis 123; Lane 4: E. faecalis 126; Lane 5: E. faecium; Lane 6: Negative control (pJF
5.5 DNA).
3.8. peR Using Primers from Dukta-~alen et al., 1995
In designing primers it is vital to test their specificities and to define the optimal conditions
for amplification (70). The Dukta-Malen et al., primers were based on the specific
detection of genes encoding D-alanine : D-alanine (D-Ala : D-Ala) ligases and related
glycopeptide resistant enzymes, since they are responsible for synthesizing D-Ala-D-Lac,
which give rise to the VanA and B-type resistance. Ligases that produce D-Ala-D-Ser are
responsible for the VanC-l resistance phenotype (38). The primer sets used were all of
similar size and GC content to prevent variations in annealing temperatures.
PCR was performed with DNA from every strain as a template. In Figure 3.24., the VanA
primer pair was used. This primer pair was targeting the vanA gene cluster and yielded a
product of the appropriate size of 732 bp for only the VanA control DNA in lane 1. This
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product was correctly amplified, hence the rest of the results did not show false negatives.







Figure 3.24. Agarose gel [1.5% (w/v)] showing PCR amplification with Primer VanA
(Dukta-Malen et al., 1995). Lane M: Molecular Weight Marker III; Lane 1: VanA
Control DNA; Lane 2: Smilleri P213; Lane 3: Smilleri P35; Lane 4: Smilleri B200; Lane
5: E. faecalis 123; Lane 6: E. faecalis 126; Lane 7: E. faecium; Lane 8: Negative Control
(No template DNA).
In the following PCR experiment, primer VanE was used for amplification. Figure 3.25.
illustrates the results obtained. A single band of an estimated size of 635 bp can be seen in
lane 1. This is the only amplificon that was produced. The VanB control DNA of the
correct size. Hence, no amplification in the other lanes, prove there are no false negatives.
This then implies that none of the bacterial strains are of the VanB phenotype.
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Figure 3.25. Agarose gel [1.5% (w/v)] showing PCR amplification with Primer VanB
(Dukta-Malen et al., 1995). Lane M: Molecular Weight Marker Ill; Lane 1: VanB Control
DNA; Lane 2: 8.milleri P213; Lane 3: 8.milleri P35; Lane 4: 8.milleri B200; Lane 5: E.
faecalis 123; Lane 6: E. faecalis 126; Lane 7: E. faecium; Lane 8: Negative Control (No
template DNA).
In the following PCR experiment, bacterial DNA was amplified with primer VanC in Figure
3.26. In lanes 1 - 6, bands of the same size can be seen. The approximate size of these
products is 822 bp correctly targeting the vane gene cluster. This indicates that 8. milleri
P213,8. milleri P35, 8. milleri B200, E. faecalis 123, E. faecalis 126 and E. faecium are all
of the VanC phenotype. This correlates with the MIC values obtained from disk-diffusion
assay. This phenotype is more commonly found in E. gallinarum. The negative control did










Figure 3.26. Agarose gel [1.5% (w/v)] showing PCR amplification with Primer VanC
(Dukta-Malen et al.,1995). Lane M: Molecular Weight Marker Ill; Lane I: milleri P213;
Lane 2: S.milleri P35; Lane 3: S.milleri B200; Lane 4: E. faecalis 123; Lane 5: E. faecalis
126; Lane 6: E. faecium; Lane 7: Negative Control (No template DNA).
3.9. Sequencing of peR Products Generated By Amplification with Dukta-Malen et
al., 1995 Primers
In order to verify whether the products obtained by PCR were the correct ones, sequencing
was performed on these products. From the sequencing results in Figure 3.27 and 3.28, the
VanA product obtained from the VanA control DNA amplified with the VanA primers
were found to be homologous to E. faecium BM4147. This confirms that this is indeed the
well-characterized glycopeptide Enterococci belonging to the VanA phenotype.
The VanB amplicons attained from the VanB control DNA amplified with the VanB
primer pair by PCR was also sequenced. The sequence can be seen in Figure 3.29. This
nucleotide sequence was found to be a hundred percent homologous to an E. faecalis
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Tn1549 transposon which validates that this is the well-characterized vancomycin-resistant
Enterococcal strain belonging to the VanB phenotype.
E. faecalis 126 amplified with the VanC primers were also sequenced. The results can be
seen in Figures 3.29 and 3.30. These sequences were found to be ninety-six percent
homologous to the E. gallinarum VanC vancomycin-resistant gene cluster. This confirms
that products obtained from PCR in Figure 3.26 were accurate and one can infer that the
other strains, S. milleri P213, S. milleri P35, S. milleri B200, E. faecalis 123 and E.
faecium were also correctly identified as VanC phenotypes.
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Figure 3.27. DNA sequencing results of VanA control DNA amplified with Primer VanA using Dukta-Malen et al., 1995 Primers.
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Figure 3.28. DNA sequencing results of VanA control DNA amplified with Primer VanA using Dukta-Malen et al., 1995 Primers.
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1 atgaatagaa taaaagtcgc aatcatcttc ggcggttgct cggaggaaca tgatgtgtcg
61 gtaaaatccg caatagaaat tgctgcgaac attaatactg aaaaattcga tccgcactac
121 atcggaatta caaaaaacgg cgtatggaag ctatgcaaga agccatgtac ggaatgggaa
181 gccgacagtc tccccgccat actctccccg gataggaaaa cgcatgggct gcttgtcatg
241 aaagaaagcg aatacgaaac acggcgtatt gatgtggctt tcccggtttt gcatggcaaa
301 tgcggggagg atggtgcgat acagggtctg tttgaattgt ctggtatccc ctatgtaggc
361 tgcgatattc aaagctccgc agcttgcatg gacaaatcac tggcctacat tcttacaaaa
421 aatgcgggca tcgccgttcc cgaatttcaa atgattgata aaggtgacaa gccggaggcg
481 ggtgcgctta cctaccctgt ctttgtgaag ccggcacggt caggttcgtc ctttggcgta
541 accaaagtaa acggtacgga agaacttaac gctgcgatag aagcggcagg acaatatgat
601 ggaaaaatct taattgagca agcgatttcg ggctgtgagg tcgggtgtgc ggtcatgggg
661 aacgaggatg
Figure 3.29. Nucleotide sequence of the VanB amplicon obtained from the peR of the VanB control amplified with VanB primers from
Dukta-Malen et al., 1995.
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Figure 3.30. DNA sequencing results ofE. faecalis 126 amplified with Primer Vane using Dukta-Malen et al., 1995 Primers.
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Figure 3.31. DNA sequencing results of E. faecalis 126 amplified with Primer Vane using Dukta-Malen et al., 1995 Primers.
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3.10. Southern Blotting Using Dukta-Malen et aI., 1995 Primers as Probes
Southern blot/hybridisation was performed on bacterial strains, using the primers obtained
from Dukta-Malen et al., 1995 as probes to confirm the results obtained by PCR analysis
and sequence analysis.
The blot in Figure 3.32. used primer VanA as a probe. In this picture one can see the DIG-
labelled Molecular Weight Marker in lane M. This indicates that the detection worked.
This blot was successful since the positive control, which was the VanA control DNA had
appeared. Hence, only the VanA sequence was detected using the VanA primer as the
probe. These results correlate with that obtained in PCR that the other bacterial strains are
not of the VanA phenotype. This also correlates with the MIC values obtained via disk
diffusion. However, in lane 8 the negative control, pJF 5.5 was also detected.
M 1 2 3 4 5 6 7 8 9
Figure 3.32. Southern blot using Primer VanA (Dukta-Malen et al., 1995) as a probe.
Lane M: Dig-labelled Molecular Weight Marker; Lane 1: S milleri P213; Lane 2: S
milleri P35; Lane 3: Smilleri B200; Lane 4: E. faecalis 123; Lane 5: E. faecalis 126;
Lane 6: E. faecium; Lane 7: VanB Control DNA; Lane 8: Negative Control (pJF 5.5
DNA); Lane 9: VanA Control.
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The VanB primer was also used as a probe for southern blot/hybridisation. The results
obtained can be clearly seen in Figure 3.33. The DIG-labelled Molecular Weight Marker
can be seen. This indicates that the detection was successful. In lane 9, the VanB control,
which was the positive control, was detected. This suggests that the absence of bands in
lanes 1 - 8 were not false negatives. Hence, these bacterial strains are not of the VanB type
vancomycin resistance. This is in concordance with results obtained in PCR and
sequencing.
M 1 2 3 4 567 8 9
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Figure 3.33. Southern blot/hybridisation using Primer VanB (Dukta-Malen et al., 1995) as
a probe. Lane M: Dig-labelled Molecular Weight Marker; Lane 1: S milleri P213; Lane 2:
S milleri P35; Lane 3: Smilleri B200; Lane 4: E. faecalis 123; Lane 5: E. faecalis 126;
Lane 6: E. faecium; Lane 7: VanA Control DNA; Lane 8: Negative Control (pJF 5.5
DNA); Lane 9: VanB Control.
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Southern blotlhybridisation was performed again on all bacterial strains, using the VanC
primers as a probe. From the blot in Figure 3.34, the DIG-labelled Molecular Weight
Marker, as well as other bands can be seen in lanes 1 - 6. This indicates that the detection
was successful. The other bands confirm the presence of the VanC sequence in the
bacterial strains used. This correlates to the PCR and sequencing performed with the same
set of primers. Hence, these strains are definitely of the VanC phenotype. The negative
control, pJF 5.5 in lane 7, did not appear. This confirms that the results are not false
positives. Under highly stringent conditions, each probe hybridised to the isolates of the
same class.
The phenotypes can also be confirmed by examining the peptidoglycan precursors
produced under induced condition by High Performance Liquid Chromatography (HPLC).
~ 1 2 3 4 5 6 7
Figure 3.34. Southern Blot using the VanC primers (Dukta-Malen et al., 1995) as probes.
Lane M: Dig-labelled Molecular Weight Marker; Lane 1: S. milleri P213; Lane 2: S.
milleri P35; Lane 3: S.milleri B200; Lane 4: E. faecalis 123; Lane 5: Efaecalis 126;
Lane 6: E. faecium; Lane 7: Negative Control (pJF 5.5 DNA).
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3.11. Analysis of Peptidoglycan Precursors
Samples of the fraction containing the cell wall precursors of each bacterial strain were
analysed by HPLC. This method is based on the separation of suspension into components
using liquid chromatography over a short period of time at a high pressure. For reverse-
phase chromatography, separation is based on the hydrophobic interaction between the
solute molecules in the mobile phase and the immobilized hydrophobic ligand in the
stationary phase. The C-18 column binds peptides tighter than proteins and thereby getting
rid of 'junk' proteins. This technique is a means of measuring the decrease in the amount
of substrate and the increase in the amount of product (83). The approximate elution times
for the precursors were: UDP-MurNAc-tripeptide, 7.7min; UDP-MurNAc-tetrapeptide,
16min; UDP-MurNAc-pentapeptide, 25min; UDP-MurNAc-pentadepsipeptide, 42min
according to the method by Baptista et al., 1997.
There are various steps that take place inside and outside the cell membrane during the
synthesis of peptidoglycan. Transglycosylation is the process whereby the carbohydrates,
N- acetyl glucosamine (GlcNAc) and the N- acetyl muramic acid (MurNAc) subunits are
put together to form the glycan chains. Transpeptidation is the peptide cross-linking
between these chains. This step involves linking the sugar portion of the peptidoglycan
subunit to the glycan backbone of the existing cell wall polymer. D-Alanine is
enzymatically removed from the end of the pre-existing peptide side chain. This allows for
the peptide side chain to be cross-linked to the recently synthesized peptidoglycan subunit.
Both these steps of peptidoglycan biosynthesis occur just outside the membrane.
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3.11.1. HPLC Profiles of Precursors Arrested With 20 J.1g/ml Vancomycin
Cytoplasmic peptidoglycan precursors were extracted after strains were grown in the
presence of vancomycin to induce the transcription of the resistant genes. Vancomycin
inhibits both transglycosylation as well as the transpeptidation steps of peptidoglycan
synthesis (34, 35). The action of this glycopeptide is restricted to these steps since the
disaccharide-pentapeptide unit is formed in the bacterial cytoplasm and only thereafter
transported across the cytoplasmic membrane. In susceptible bacterial strains, vancomycin
exposure leads to the accumulation of the lipid-associated disaccharide pentapeptide (lipid
intermediate II) in the membrane. This gives rise to the inhibition of the transglycosylation
step in which the emergent peptidoglycan polymer is extended by a single disaccharide-
pentapeptide at the reducing end. The bottom surface of vancomycin makes five hydrogen
bonds to the D-Ala-D-Ala amino acids at the end of the peptide cross-bridges, thus
sterically inhibiting transpeptidation. This antibiotic also prevents these residues from
being easily reachable to the active site of the transpeptidases because of its high affinity.
Peptide cross-linking therefore cannot occur, thus resulting in cell lysis. Hence,
vancomycin only affects the late stage reactions in peptidoglycan synthesis. One of the
effects is that vancomycin resistance is not being expressed and only the normal UDP-
MurNAc-pentapeptide precursor is produced (2, 19). The increasing concentration of D-
Ala-D-Ala corresponds to the increasing inactivation of vancomycin (2).
In vancomycin resistant strains, such as Enterococci, a major portion of the lipid
intermediate II molecules have the peptidoglycan precursor terminating in D-Ala-D-Lac
instead of the normal D-Ala-D-Ala. This implies that transglycosylation is resistant to
vancomycin since this antibiotic can now form only four hydrogen bonds with this
terminus. This causes the binding affinity to decrease by a thousand fold (51).
Transglycosylation is therefore not repressed except at a high concentration of the
antibiotic (1).
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The HPLC chromatogram in Figure 3.35 shows the results of the chemical analysis of the
cell wall precursor pool of S. milleri P213 grown in the presence of vancomycin at twice
its MIC value, i.e., 20 f.!g/ml, as determined by the disk-diffusion assay. The major
component of the precursor pool in this strain was UDP-MurNAc-pentapeptide at
approximately 20 minutes. At 14 minutes, a lower amount of UDP-MurNAc-tetrapeptide
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Figure 3.35. HPLC analysis of peptidoglycan precursors from S. milleri P213 arrested
with 20 f.!g/ml vancomycin at OD252.
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The separation of peptidoglycan precursors of S. milleri P35 by HPLC can be seen in the
chromatogram in Figure 3.36. From this figure, a high proportion of UDP-MurNAc-
tetrapeptide can be seen at 17 minutes. At 39 minutes a moderate amount of UDP-
MurNAc-pentadepsipeptide was present.
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Figure 3.36. HPLC analysis ofpeptidoglycan precursors from S. milleri P35 arrested
with 20 I-tg/ml vancomycin at OD252
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Cell wall peptidoglycan precursors ofS. milleri B200 separated by HPLC is represented by
the chromatogram in Figure 3.37. Peptidoglycan precursors were arrested with 20 Ilg/ml
of vancomycin. In this figure, a small amount of UDP-MurNAc-tripeptide at Ilminutes
was present, followed by a high proportion of UDP-MurNAc-tetrapeptide at 14 minutes.
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Figure 3.37. HPLC analysis of peptidoglycan precursors from S. milleri B200 arrested
with 20 Ilg/ml vancomycin at OD252
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Figure 3.38 represents the separation of the precursors of E. faecalis 123 induced with
vancomycin at a concentration of twice its MIC. Only a high amount of UDP-MurNAc-
pentadepsipeptide was seen at roughly 39 minutes.
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Figure 3.38. HPLC analysis of peptidoglycan precursors from E. faecalis 123 arrested
with 20 ~g/ml vancomycin at OD252.
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HPLC analysis of peptidoglycan precursors from E. faecalis 126 arrested with 20 I-lg/ml
vancomycin at OD252 is illustrated in Figure 3.39. E. faecalis 126 contained a moderate
amount of UDP-MurNAc-tripeptide as can be seen by the peak between 14 - 16 minutes.
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Figure 3.39. HPLC analysis of peptidoglycan precursors from E. faecalis 126 arrested
with 20 I-lg/ml vancomycin at OD252.
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The HPLC chromatogram in Figure 3.40. represents the separation of the precursors found
in the E. faecium bacterial strain. In this chromatogram, the first peak at 10minutes is
representative of the UDP-MurNAc-tripeptide precursor. UDP-MurNAc-tetrapeptide was
seen at a high proportion at 15minutes, followed by a moderate amount ofUDP-MurNAc-
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Figure 3.40. HPLC analysis of peptidoglycan precursors from E. faecium arrested
with 20 Ilg/ml vancomycin at OD252
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The relative proportion of peptidoglycan precursor of the VanA control separated by
HPLC is illustrtated by Figure 3AI. In this chromatogram, a large proportion of UDP-
MurNAc-tetrapeptide can be inferred by the peak at approximately 17 minutes. The
moderate peak at 39 minutes represents the UDP-MurNAc-pentadepsipeptide precursor.
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Figure 3.41. HPLC analysis of peptidoglycan precursors from VanA control arrested
with 20 ~g/ml vancomycin at OD252
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HPLC analysis of peptidoglycan precursors from VanB control arrested with 20 )..I.g/ml
vancomycin can be seen in Figure 3.42. Peak 1 at 15minutes was of the UDP-MurNAc-
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Figure 3.42. HPLC analysis of peptidoglycan precursors from VanB control arrested
with 20 )..I.glml vancomycin at OD252
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In summary (Table 3.2), only S. milleri B200 and E faecium showed a relatively small
amount of UDP-MurNAc-tripeptide present. All strains, except for E faecalis 123
contained the cytoplasmic peptidoglycan precursor, UDP-MurNAc-tetrapeptide in large
proportions. UDP-MurNAc-pentapeptide was seen for most of the strains in moderate
amounts, except in E faecalis 123 and the VanA control. However, S. milleri P35, E
faecalis 123 and the VanA control seemed to have the precursor, UDP-MurNAc-
pentadesipeptide.
Table 3.2. Summary of the peptidoglycan precursors accumulated analysed by HPLC
Strain Tri-peptide Tetra-peptide Penta-peptide Pentadepsi-peptide




























S. milleri P213 X XX
S. milleri P35 XXX XX
S. milleri B200 XXX XX
E faecalis 123 X XX XXX
E faecalis 126 XXX
Efaecium XXX XX
VanA Control XXX X
VanB Control XXX XX
X shows a small amount of precursors accumulated
XX - shows a moderate proportion ofprecursors accumulated
XXX - shows a relatively large amount of precursors accumulated
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De Jonge et al., 1996, found in their studies that UDP-MurNAc-tetrapeptide was produced
abundantly and identified as the major dimer. The reason this occurs is because
vancomycin obstructs the integration of pentapeptides (D-Ala-D-Ala) and the most
appropriate acceptors available in the transpeptidation reaction are tetrapeptides (6, 33).
Now that the tetrapeptide is the appropriate acceptor, depsipeptide precursors can be used
as donors in the transpeptidation reaction (33). The terminal residue of the donor result in
the peptidoglycan deficient lactate residues leading to the formation of tetrapeptides from
the pentapeptides (33). UDP-MurNAc-tetrapeptide-D-Lac has a lower affinity for
vancomycin and its accumulation when peptidoglycan synthesis is inhibited by
vancomycin implies that the active site is inside the cytoplasm (19). Billot-Klein et al.,
1996, found in their studies that after the induction of vancomycin resistance, a lingering
amount of normal UDP-MurNAc- pentapeptide was present during the synthesis of the
new UDP-MurNAc-tetrapeptide phenotype (19).
The presence of tetrapeptides can also be attributed to VanY hydrolysing cytoplasmic
peptidoglycan precursors and does not act as an intermediate in precursor synthesis (6,33).
The precursor can then be incorporated into the cell wall and acts as an acceptor in
transpeptidation reactions. This allows for the sufficient cross-linking for cell wall
integrity. This is afforded only if there are adequate D-Ala-D-Lac ending precursors to act
as donors. This step is necessary for resistance since it involves the removal of D-Ala-D-
Ala ending precursors (6). D-lactate is incorporated into the UDP-muramyl precursor as
D-Alanyl-D-Lactate, forming a depsipeptide, which is now resistant to vancomycin
binding (52). This substitution in peptidoglycan production prevents binding of
vancomycin to the cell wall components and allows the polymerisation of peptidoglycan in
the presence of the antibiotic (5). Strains that are now resistant rely completely on
production of peptidoglycan precursors containing D-Ala-D-Lac for growth (35). The
presence of UDP-MurNAc-tetrapeptide and altered peptidoglycan cross bridges contribute
to resistance (19).
In resistant strains, the D, D carboxyesterase activity is responsible for enzymatically
excising the lactate residue from the stem peptide. This is possible because the resistant
strain has the vanY gene. This gene is implicated in the removal of the D-Alanine residue
from the D-Ala-D-Ala pentapeptide precursor. It is also proposed to have a highly
selective hydrolytic activity for the depsipeptide bonds. D-Alanine infiltrates the
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cytoplasm and fuels the synthesis ofthe pentapeptide. This is done by VanY, which is aD,
D-carboxypeptidase. This enzyme contributes to vancomycin resistance by hydrolysing D-
Ala or D-Lac of peptidoglycan precursors (6). However, this enzyme is not sufficient for
resistance. VanY can remove pentapeptide at the expense of the formation of some
tetrapeptide from pentadepsipeptide thereby increasing the level of resistance (5, 6). The
production of pentapeptide together with pentadepsipeptide leads to susceptibility to the
antibiotic (6). In resistant strains, the pentapeptide is more efficient at competing for the
binding of vancomycin (19). In vancomycin-induced cells, a portion of the cytoplasmic
membrane reduces the access of vancomycin to the pentapeptide. The D-Ala-D-Ala
moiety of the pentapeptide prevents binding of vancomycin by preventing binding of the
induced protein to the pentapeptide leading to the ensuing alterations and this is the most
probable mechanism of vancomycin resistance. The pentapeptide binding sites appears to
be similar to enzymes that bind D-Ala-D-Ala. These enzymes are those that are utilized in
the metabolism of the dipeptide, or the pentapeptide, or in the polymerisation of the
disaccharide-pentapeptide. The task of these proteins resembles those of a
carboxypeptidase or of a transpeptidase. The transformed cell shape of vancomycin-
induced strains implies that the normal synthesis of peptidoglycan by the cell wall enzymes
does not occur. Normal synthesis is prevented because of the proteins binding to the
customized pentapeptide (2).
Since these strains are of the VanC phenotype, the VanC ligase favours the production of a
pentapeptide. The pentapeptide terminates in D-Ala-D-Ser and weakens the binding of the
antibiotic to the new pentapeptide. VanT, which is a serine racemase, VanC D-Ala : D-Ser
ligase and VanXYc is responsible for the synthesis of D-serine by eliminating the D-Ala
terminating peptidoglycan precursor (27). This last enzyme, VanXYc has a very low
dipeptidase activity against D-Ala-D-Ser and has no activity against UDP-MurNAc-
pentapeptide terminating in D-Ser. The elimination of D-Ala is catalyzed by this single
protein, VanXYc in order to purge 'susceptible' precursors. However, the accumulation of
tetrapeptides indicates that the elimination ofD-Ala-D-Ala is not complete (4).
Cells that express the vanA gene complex usually have UDP-MurNAc-pentapeptide in the
wall precursor pool. This precursor does not inhibit the D-Ala : D-Ala ligase activity since
VanA cannot hamper the binding of vancomycin to its target. This occurs because an
alternative cell wall biosynthetic pathway is activated. The vancomycin-sensitive step is
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avoided, by producing an abnormal cell wall precursor in which the dipeptide D-Ala-D-
Ala is substituted by D-Ala-D-Lac, which is vancomycin-insensitive (94). VanA and
VanB facilitate the synthesis of pentadepsipeptides ending in D-Ala-D-Lac since they are
structurally similar (12, 27). Vancomycin resistance of both the VanA and VanB control
are due to the assembly of these peptidoglycan precursors that bind to vancomycin with
reduced affinity. Arthur et al., 1992, propose that in resistant cells, the pathway for the
peptidoglycan precursor production is by depsipeptide synthesis (10).
3.11.2. HPLC Profiles of Precursors Arrested With 100 Ilg/m1 Bacitracin
Bacitracin was used to amplify the cell wall precursors from each of the bacterial strains.
It is an antibiotic produced by strains of Bacillus licheniformis and is a mixture of high
molecular weight polypeptides, which acts bactericidally (82, 97). This antibiotic is an
inhibitor of the lipid phosphatase in which the N-acetylmuramyl peptide is transferred from
UDP to a lipid carrier (82). It is then modified to form a complete emerging peptidoglycan
subunit. This process occurs on the inner surface of the cytoplasmic membrane and ends
with the translocation of the terminated subunit to the exterior of the cytoplasmic
membrane. Hence, bacitracin inhibits the dephosphorylation reaction and in the absence of
monophosphorylated carrier peptidoglycan synthesis stops. Normally the peptidoglycan
subunit is passed across the cytoplasmic membrane attached to the undecaprenol
diphosphate. After the growing peptidoglycan monomer leaves the carrier on reaching the
cell wall, the undecaprenol diphosphate is dephosphorylated to its monophosphate form
(91). This reaction is essential for restoration of the lipid carrier required for the cyclic
synthesis of peptidoglycan (97). Therefore, bacitracin is also thought to induce resistance
since one of its main targets is subsequent the transglycosylation step which polymerises
the intermediates into peptidoglycan (14). Therefore, inhibition of peptidoglycan
polymerisation is critical for induction (12).
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Figure 3.43. represents the cytoplasmic peptidoglycan precursor of S. milleri P213 arrested
with 100 !-tg/ml. The relatively small peak at 15 minutes is that of UDP-MurNAc-
tetrapeptide. At 27 minutes, a fairly moderate amount of UDP-MurNAc-pentapeptide was
seen.
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Figure 3.43. HPLC analysis of peptidoglycan precursors from S. milleri P213 arrested
with 100 !-tg/ml bacitracin at OD252.
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Analysis of the peptidoglycan precursor of S. milleri P35 by HPLC can be seen in Figure
3.44. A high proportion ofUDP-MurNAc-tetrapeptide was present at 15 minutes, whilst a
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Figure 3.44. HPLC analysis of peptidoglycan precursors from S. milleri P35 arrested
with 100 )..Lg/ml bacitracin at OD252 .
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Peptidoglycan precursor of S. milleri B200 was extracted and analysed in Figure 3.45. The
chromatogram showed a high amount of UDP-MurNAc-tetrapeptide eluted at 15 minutes
followed by a moderate proportion ofUDP-MurNAc-pentapeptide at 20 minutes.
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Figure 3.45. HPLC analysis of peptidoglycan precursors from S. milleri B200 arrested
with 100 /-lg/ml bacitracin at OD252
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HPLC analysis of peptidoglycan precursors from E. faecalis 123 arrested with 100 Ilg/ml
bacitracin at OD252 is represented by the chromatogram in Figure 3.46. A relatively small
amount of UDP-MurNAc-tripeptide was present compared to the moderate amount of




Figure 3.46. HPLC analysis of peptidoglycan precursors from E. faecalis 123 arrested
with 100 Ilg/ml bacitracin at OD252•
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The chromatogram in Figure 3.47. shows the HPLC analysis of the cytoplasmic
peptidoglycan precursor of E. faecalis 126 extracted with bacitracin. A relatively high








Figure 3.47. HPLC analysis of peptidoglycan precursors from E. faecalis 126 arrested
with 100 flg/ml bacitracin at OD252.
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HPLC separation of cytoplasmic peptidoglycan precursor of E. faecium is shown in Figure
3.48. This figure shows a high amount of UDP-MurNAc-tetrapeptide present at 16
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Figure 3.48. HPLC analysis of peptidoglycan precursors from E. faecium arrested
with 100 ~g/ml bacitracin at OD252.
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The cytoplasmic peptidoglycan precursor of the VanA control is analysed by HPLC as can
be seen in Figure 3.49. This chromatogram showed a high amount of UDP-MurNAc-
tetrapeptide eluted at 15 minutes. This chromatogram also illustrates a relatively small
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Figure 3.49. HPLC analysis of peptidoglycan precursors from VanA control arrested
with lOO !-tglml bacitracin at OD252
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Two peaks can be seen in the HPLC chromatogram in Figure 3.50. This figure is that of
the cytoplasmic peptidoglycan precursor of the VanB control extracted with bacitracin.
The first peak at 15 minutes represents UDP-MurNAc-tetrapeptide found in a relatively
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Figure 3.50. HPLC analysis of peptidoglycan precursors from VanB control arrested
with 100 Ilglml bacitracin at OD252.
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A summary of the results obtained can be seen in Table 3.2. Analyses of the cytoplasmic
peptidoglycan precursors arrested with bacitracin showed that UDP-MurNAc-tripeptide
was present only in the bacterial strain, E. faecalis 123. Most of the strains except E.
faecalis 126 had the precursor UDP-MurNAc-tetrapeptide. This precursor was found in
relatively large amounts. UDP-MurNAc-pentapeptide was found in moderate amounts in
all strains except in E. faecalis 126. Whilst E. faecalis 126 was the only strain to contain
the UDP-MurNAc-pentadepsipeptide precursor.
Bacitracin is thought to lead to the accumulation of cytoplasmic peptidoglycan precursors,
UDP-MurNAc-pentapeptides since it follows transglycosylation. As expected, all the
strains accrued this precursor, except for E. faecalis 126. However, the presence ofUDP-
MurNAc-tetrapeptide should not have occurred. The presence of tetrapeptides implies that
the eradication ofD-Ala-D-Ala was partial. The elimination of the D-Ala-D-Ala precursor
is vital for resistance since the attachment of the antibiotics to the lipid intermediate II at
the outer surface of the membrane is expected to remove the lipid carrier. This prevents
the incorporation of the D-Ala-D-Lac precursor into peptidoglycan (6). The lack of
pentadepsipeptides being detected suggests that D-Ala-D-Ala was not incorporated into the
peptidoglycan. If this precursor is not incorporated into the growing peptidoglycan, then
the cell must surely be resistant to the antibiotic, vancomycin, since under normal
conditions, a cell that is susceptible to the action of vancomycin would have the normal D-
Ala-D-Ala precursor. This again confirms that these strains are resistant strains.
The trends obtained for precursors with the arrest by bacitracin are very similar to that
accumulated by vancomycin, in that a large amount of tetrapeptides were present. This
was followed by a moderate amount of UDP-MurNAc-pentapeptides in each strain, except
in E. faecalis 126. By synthesizing the peptidoglycan precursor, UDP-MurNAc-
pentapeptide, these resistant strains avoid the inhibition of cell wall assembly by
vancomycin and bacitracin. It has been suggested that the accumulation of cell wall
precursors may be the signal that prompt the expression of resistant genes in these strains.
The precursors obtained from HPLC analysis are not conclusive enough based only on
their retention times. Consequently mass spectrometry was performed to confirm these
precursors.
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3.12. Analysis of Mass Spectrometry Data
Peaks of the precursors following HPLC were collected at the appropriate retention times.
Mass spectrometry was performed on these samples in order to determine the molecular
masses to reaffirm the appropriate precursors.
A summary of the molecular masses obtained is shown in Table 3.3. The molecular
masses of the normal precursors are the mass calculated, in the table. The mass observed
is the molecular mass obtained by mass spectrometry with a difference of one m/z. By
comparing the mass observed and those calculated they are closely related. This confirms
that the peaks obtained during HPLC analysis at the various retention times were in fact
the correctly identified precursors.
Table 3.3. Molecular masses of the peptidoglycan precursors isolated from the bacterial
strains
Peaks Mass Observed Mass Calculated
Tri - peptide 1284 +/- 1 m/z 1286.16
Tetra - peptide 1376 +/- 1 m/z 1375.16
Penta - peptide 1462 +/- 1 m/z 1464.16
Penta - depsipeptide 1481 +/- 1 m/z 1480.16
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CHAPTER FOUR
CONCLUSION AND FUTURE PROSPECTS
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To effectively harness and contain the spread of the prevalence of vancomycin resistance
in strains such as Streptococci, Enterococci and Staphylococcus aureus, high-throughput
screening methods need to be in place. The current conventional screening methods are
not efficient enough to detect the presence of resistant determinants because of the
increasing changes in susceptibility patterns of pathogenic organisms. Molecular assays
are now being applied for the detection of resistance genes and prove to be more superior
and advanced in identifying the presence of the resistant genes in bacterial strains.
However, molecular based detection requires the correct tools to provide the answers. A
key factor used in these assays is the appropriate sequence of oligonucleotides, used as
primers in PCR, as probes in southern blot/hybridisation and also for DNA sequencing.
The first set of primers chosen, were based on those used by Miele et al., 1995. The results
obtained from PCR, southern blotlhybridisation and DNA sequencing using these primers
was inconclusive. The results did not relate to each other and were also discrepant with the
MIC values obtained.
The second set of primers developed by Dukta-Malen et al., 1995, proved to be successful
in screening for resistance determinants in the strains used in this study. Results obtained
from the southern blots and sequencing reaffirmed accurately those attained by PCR.
These also relate to the MIC values. This implies that the genotypes of the strains were
reliably correlated with their phenotypes. This proves that PCR is efficient and consistent
enough to be used in the elucidation of vancomycin resistant genes. It is also convenient
since it is a rapid and simple technique that is sensitive enough to also detect low-level
resistance such as that of the VanC phenotype. The addition of already well-characterized
vancomycin resistant Enterococci served as a guide to differentiate the false positives from
the false negatives.
Additional analysis was performed using HPLC. This method took a closer look at the
cytoplasmic peptidoglycan precursors arrested with the antibiotics, vancomycin and
bacitracin. The accumulation of UDP-MurNAc-tetrapeptides and UDP-MurNAc-
pentapeptides further confirmed the resistance status of these strains. The molecular
masses obtained by mass spectrometry correctly identified the precursors. Hence, in this
study the confirmatory tests were accurately concurrent with the conventional phenotypic
screening tests. From this study, the conventional screening method, such as susceptibility
testing via micro-titre plate dilution or disk-diffusion assays should serve as a first screen.
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However, PCR seemed to be the most specific, reliable and rapid amongst the assays
tested, in particular for the detection of VanC resistant genes, which have low levels of
resistance to vancomycin.
Innovative techniques must be developed for the rapid microbiological diagnosis of these
strains. Pulsed-Field Gel Electrophoresis (PFGE) seems to be a useful discriminatory
DNA-based technique that provides reproducible results. Another promising method for
the detection of resistant genes and mutational resistance is DNA microarray technology
(98). The continued research into the development of new drugs and sound drug design
offer the prospect of possible eradication of the emerging resistant phenotypes. The key to
solving this problem is to find an antibiotic that is active against these strains, one that
binds to peptidoglycan precursor terminating with the depsipeptide, D-Ala-D-Lac.
Another would be to find an inhibitor of the D-Ala: D-Ala ligase (5). A set of
carbohydrates derivatives of vancomycin that are active against bacterial strains that are
resistant were discovered (48). Long-term solutions, such as vaccine-based
immunotherapies and gene therapies need to be explored to abolish the problem of drug
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